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ABSTRACT 
 
UNDERSTANDING THE SOLID STATE, SOLUBILITY AND DISSOLUTION 
BEHAVIOR OF CEFUROXIME AXETIL DIASTEREOMERS IN INTERACTIVE 
MIXTURE FORMULATIONS  
 
 
By 
Namita Dalal 
December 2015 
 
Dissertation supervised by Ira S. Buckner, Ph.D. 
 The objective of the first part of this work was to understand the solid-state and 
solution behavior of a cephalosporin antibiotic prodrug, cefuroxime axetil (CFA). CFA is 
present in commercial products as a mixture of diastereomers, which commonly form 
eutectic mixtures. A phase diagram was constructed utilizing differential scanning 
calorimetry. It was observed that the diastereomers formed a eutectic mixture with a 
composition of 75 % isomer B and a melting temperature of 124.8±0.5 °C. Phase 
solubility studies on diastereomer mixtures of various compositions showed that the 
diastereomers interacted to form a complex in solution. This interaction resulted in a 
solubility increase upon use of certain diastereomer combinations over any individual 
diastereomer. 
v 
 
 A second major objective of this project was to study the dissolution behavior of 
interactive mixtures containing CFA. Mechanically stable interactive mixtures were 
prepared utilizing the amorphous and crystalline forms of the drug with hydrophilic 
carrier particles. The dissolution rate of CFA was significantly higher from interactive 
mixtures compared to both physical mixtures and pure drug agglomerates. The 
enhancement in dissolution rate by interactive mixing was attributed to a decrease in 
fraction of agglomerated drug particles and agglomerate particle size. Both these factors 
produced an increase in effective surface area of drug available for interaction with the 
dissolution medium. 
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Chapter 1: Introduction 
 
1.1 Background to Solid-State Chemistry of Chiral Drugs 
 More than half of commercialized Active Pharmaceutical Ingredients (APIs) are 
chiral. API chirality may be essential for the biological activity of the compound. The 
stereoselectivity of chiral drugs in pharmacology and toxicology has been studied 
extensively. Stereoselectivity is based on differences in interactions between different 
enantiomers and diastereomers of drugs having receptors and enzymes in the body, which 
are themselves chiral.1, 2 In addition to the differences in the pharmacological effects of 
chiral drugs, the physical properties of enantiomers, racemates, and diastereomers differ. 
These differences can potentially affect the pharmacokinetic profile of the administered 
drug and the development of a reliable and efficacious formulation and manufacturing 
process. The following section provides an overview of the different solid-state structures 
of chiral drugs and their analysis by commonly used techniques in literature. 
1.1.1 Enantiomers, Racemates, and Diastereomers 
 Compounds with the same molecular formula but different chemical structures are 
known as isomers. Unlike constitutional isomers that differ in the order in which the 
atoms are connected (or functional groups), stereoisomers contain the same functional 
groups; however, differ only in the arrangement of atoms in space. Optical isomerism is a 
type of stereoisomerism which arises from differences in the three-dimensional 
relationship of substituents around one or more atoms. Enantiomers are optical isomers 
that are non-superimposable mirror images of each other. An equimolar mixture of 
enantiomers is known as a racemic mixture or racemate. Diastereomers are pairs of 
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compounds that contain more than one chiral center, all of which are not 
superimposable.3 Unlike enantiomers, diastereomers do not differ in configuration around 
all of the asymmetric carbon atoms. Consequently, the distances between non-bonded 
atoms are different, causing changes in the overall conformation and polarities of 
diastereomers. Each diastereomer molecule packs differently in a crystal lattice; 
therefore, their crystals differ in physical properties such as solubility and melting 
points.4 Conversely, enantiomers have the same physical properties and behave 
differently when exposed to polarized light or when participating in a chemical reaction 
catalyzed using a chiral compound, such as enzymes in the body.5, 6 
 Enantiomers and diastereomers may differ considerably in their pharmacological 
and toxicological effects because they commonly interact with stereoselective biological 
macromolecules such as enzymes and receptors. However, synthesizing chiral drugs in an 
achiral environment leads to the formation of a racemic mixture. Unless a considerable 
disadvantage is associated with the use of a particular enantiomer over a racemic mixture, 
the mixture is most commonly employed because of the difficulty in resolving a racemic 
mixture into single enantiomers.1 Because diastereomers have different solubilities, they 
can be separated using solvent extraction methods. Diastereomeric salt formation, chiral 
chromatography, and enzymatic separation are used to separate and resolve enantiomers.1 
 Differences between enantiomers and diastereomers influence how they pack in a 
crystalline lattice. Although an understanding of the solid-state behavior of diastereomers 
of cefuroxime axetil (CFA) is relevant to this project, a detailed description of phase 
diagrams and the solid-state packing behavior of enantiomer systems is also presented 
(Section 1.1.2 and 1.1.3). Because crystallization of diastereomers from an equimolar 
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mixture can potentially produce one of several solid-state structures, a thorough 
knowledge of the possible types of binary solid-liquid phase diagrams and the solid-state 
structure they represent is essential when considering the crystallization of chiral drugs 
from their mixtures. 
1.1.2 Molecular Interactions and Solid-State Structures of Chiral Drugs 
 Differences in the strength and type of interactions between molecules with same 
chirality and those between molecules with opposite chirality can have a significant effect 
on the physical properties, namely solubility, of crystalline structures of chiral 
compounds. Homochiral interactions are defined as intermolecular, non-bonded 
attractions or repulsions in assemblies of molecules with same chirality, whereas 
heterochiral interactions are those between molecules with different chirality. Homochiral 
and heterochiral interactions are unlikely to be equivalent (∆Ghomo ≠ ∆Ghet, where G is the 
Gibbs free energy) because they are diastereomeric in nature. This difference is 
negligible in the gaseous or liquid state, or in an achiral solvent. However, these 
differences are substantial to result in different physical properties of pure enantiomers or 
diastereomers and racemates in a chiral medium or in the crystalline state.1, 5, 7 
 Mostly, crystallization from a racemic mixture yields a mixture of homochiral 
(racemic conglomerate) or heterochiral (racemic compound) crystals (Figure 1.1a and 
Figure 1.1b, respectively). A racemic conglomerate is an equimolar physical mixture of 
homochiral crystals of two enantiomers that is mechanically separable. A racemic 
compound is a heterochiral crystal (contains opposite enantiomers in the crystal lattice). 
In some cases, the opposite enantiomers are arranged randomly in a crystal lattice as a 
solid solution (also known as pseudoracemate) (Figure 1.1c). Racemic compounds are 
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generally more abundant (90–95 % of crystalline racemates) than racemic conglomerates 
(5–10 % of crystalline racemates). A higher occurrence of mixed crystals is due to their 
higher entropy than their homochiral counterparts.1  
 
 
Figure 1.1. Solid-state packing of chiral drugs (a) Racemic conglomerate (mixture of homochiral 
crystals) (b) Racemic compound (heterochiral or paired enantiomers) (c) Solid solution 
(pseudoracemate or randomly arranged enantiomers). 
 
 Unlike racemic mixtures that generally yield heterochiral crystals, diastereomers 
usually crystallize from an equimolar solution as a conglomerate. Solvent extraction 
methods can be used to further separate the individual diastereomers forming the 
conglomerate based on the differing polarities of the diastereomers. 
 To ascertain the type of crystalline structure that chiral drugs can form on 
crystallization, phase diagrams are constructed. The next section describes in detail the 
use of phase diagrams for investigating the solid-state structure of chiral drugs. 
1.1.3 Phase Diagrams of Chiral Drugs 
 The melting point phase diagram (solid-liquid phase diagram), which is 
determined using thermal methods, can be used to ascertain the solid-state structure of 
chiral drugs on crystallization. A solid-liquid phase diagram graphically represents the 
thermodynamic conditions (temperature and composition) at which solid and liquid 
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phases can exist in equilibrium. It consists of two equilibrium lines: (i) the liquidus line 
marking the equilibrium temperature at which a liquid of a given composition starts to 
crystallize; (ii) the solidus line reflecting the temperature below which a liquid cannot 
exist in equilibrium.2 
 Various thermal methods, such as differential scanning calorimetry (DSC), 
differential thermal analysis (DTA), and hot-stage microscopy (HSM), are available to 
determine the solid-liquid phase diagram. These methods involve detecting the solid to 
liquid phase change as a function of temperature and composition. Of the thermal 
methods, DSC analysis is preferred because of its small sample size requirement and 
ability to use slow heating and cooling rates for better resolution of thermal events. For 
DSC analysis, mixtures containing various ratios of enantiomers or diastereomers are 
prepared. In DSC, for thermally stable materials, the mixtures are heated in situ to form a 
fused mass and subsequently cooled. The melting points of the thermal events observed 
in the second heating cycle are recorded and plotted against the mixture composition. 
Although thermal methods are most widely employed to construct phase diagrams, 
caution must be exercised in their use to obtain reproducible results free from the 
confounding effects of polymorphism exhibited by many organic compounds. The use of 
thermal methods is limited to compounds that are thermally stable and non-volatile in the 
temperature range used. Furthermore, the method of sample preparation and heating and 
cooling rates employed are crucial for producing an accurate equilibrium phase diagram. 
Heating rate affects the temperature at which thermal transitions are observed and 
thermal events are resolved. In general, an increase in the heating rate shifts melting 
temperatures to higher values because of thermal lag effects and results in decreased 
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resolution of thermal events. Because melting temperature is required for constructing 
phase diagrams from thermal data, it must be corrected for the effects of heating rate. 
This correction involves heating individual samples of each mixture composition at 
different heating rates and recording the onset or peak melting temperatures. The melting 
temperatures are then plotted against the heating rate, and the intercept of this plot, which 
represents the extrapolated melting temperature at zero heating rate, is used to construct 
the phase diagram. The phase diagram of a racemic or diastereomer conglomerate shows 
typical eutectic behavior. Eutectics are intimate mixtures of two distinct crystal forms 
that are miscible in the liquid state. The unique property of a eutectic is that it has a lower 
melting point than pure components.8, 9 For a racemic conglomerate, the liquidus 
temperature at the equimolar point lies below all other liquidus temperatures, making the 
equimolar point the eutectic composition and the temperature the eutectic temperature 
(Figure 1.2a). Conversely, diastereomer conglomerates also exhibit eutectic behavior; 
however, the eutectic composition does not necessarily occur at the equimolar point 
(Figure 1.2b). 
 Figure 1.2c represents the phase diagram obtained when enantiomers crystallize 
from an equimolar mixture to form a racemic compound (heterochiral crystal). The shape 
of the diagram can vary depending on whether the melting point of the racemic 
compound is higher or lower than that of the pure enantiomers. The phase diagram is 
symmetrical around a central vertical line, and the racemic compound is a new crystalline 
phase that forms eutectic mixtures with the two enantiomers.8, 9 Diastereomers have 
different physical properties and typically do not form heterochiral crystals. However, the 
formation of a particular crystal (homochiral or heterochiral) depends on differences in 
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their structures making it vital to understand the different types of phase diagrams and the 
solid-state structure they represent. 
 
 
Figure 1.2. Typical phase diagram of melting point versus composition: (a) Racemic 
conglomerate of enantiomers; (b) Conglomerate of diastereomers; (c) Racemic compound; 
D and L represent a pair of enantiomers, R and S represent a pair of diastereomers, C-
conglomerate, RC-racemic compound. 
 
1.2 Solubility and Dissolution Studies on Multicomponent Mixtures 
1.2.1 Phase Solubility Analysis 
 When a solute is placed in a solvent, the solute molecules break away from the 
solid surface. Some solute molecules redeposit on the bulk solute surface, whereas others 
move randomly into the solvent to form a solution. Once sufficient solute molecules have 
populated the bulk solvent, the rate of molecules leaving the solute surface becomes 
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equal to the rate of deposition (dynamic equilibrium). The solute concentration in the 
solvent at which this equilibrium is reached is known as the saturation solubility or 
equilibrium solubility. The saturation solubility of a pure compound in a given solvent, at 
a given temperature and pressure, is a characteristic physical property of the substance, 
and may, therefore, be used as a criterion of purity. If a sample containing the 
thermodynamically stable crystalline form of pure compound exhibits solubility in excess 
of that expected, the additional quantity may be ascribed to the presence of a second 
component, such as an impurity. In case of pure compounds, the experimental operation 
of measuring saturation solubility consists of adding excessive solid sample to a constant 
volume of solvent in which the solid is slightly soluble. The systems are brought to 
equilibrium by prolonged agitation at a constant temperature. The solution phases are 
then analyzed for total solute content, mostly by using spectroscopic or chromatographic 
assay methods. The experimentally determined solution concentration (usually expressed 
in mg/mL or M) can be plotted against time to illustrate dissolution behavior. Initially, 
the solid dissolves and the concentration increases. This increase occurs until the solution 
becomes saturated with respect to the compound, following which a line with a zero 
slope is obtained. Extrapolation of this line to the vertical axis yields the saturation 
solubility of the compound. Similarly, for a mixture of components, the solubilities of the 
individual components can be determined using a method similar to that used to measure 
the solubility of a pure compound, provided that the solubility of each component is not 
affected by the other component(s) present. However, many systems do not exhibit this 
ideal behavior and undergo molecular interactions to form complexes in solution. In case 
of interaction, the differentiation between the amount of free compound dissolved and 
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that dissolved in combination with the other component complicates solubility 
measurements. The types of phase solubility diagrams obtained in this case are described 
in detail as follows. 
 The general experimental operation in studying molecular interactions by means 
of solubility measurements entails adding an excess amount of a slightly soluble 
compound (X) to a fixed volume of solvent at a certain temperature according to the 
method of Higuchi and Connors.10 Then, successively increasing portions of a relatively 
soluble compound (Y) is added to the vessels, which is sealed and equilibrated at 
constant temperature. The solution phase is then analyzed for the total solution 
concentration of X, regardless of its molecular state. A phase diagram is constructed by 
plotting the total molar concentration of X in the solution phase on the vertical axis 
against the molar concentration of Y added to the system. The following phase diagrams 
are commonly obtained: 
(a) Type A diagrams: These show an apparent increase in the solubility of X caused 
by component Y. 
(b) Type B diagrams: These show a decrease in the solubility of X caused by 
component Y. 
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(a) Type A diagrams (Figure 1.3) 
 
 
Figure 1.3. Phase-solubility diagrams of Type A systems showing an apparent increase in 
solubility of X caused by Y. Adapted from Higuchi and Connors.10 
 
 Xt represents the total molar concentration of dissolved X, and Yt is the total 
concentration of Y. X0 represents the equilibrium solubility of X in the absence of Y. A 
linear increase in solubility is represented by line AL, whereas positive and negative 
curvatures in the line are indicated by AP and AN, respectively. Type A diagrams indicate 
the formation of soluble complexes between X and Y. A solid phase containing pure X is 
always present; therefore, the thermodynamic activity of free X in solution is constant. 
 If complexes are of the first order in Y or may be written as XmY (where m is the 
number of moles of X in the complex), then a Type AL diagram is observed. If they are of 
a higher order in Y, such as XYn (where n is the number of moles of Y in the complex), a 
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Type AP diagram is observed. The origin of a Type AN diagram is uncertain. It may be 
associated with a change in the complex formation constant or self-association of Y at 
high concentrations. In certain instances, Type A diagrams may exhibit a plateau level of 
X that additional quantities of Y do not alter. This may be due to the disappearance of 
solid X from the system by its complete solubilization. To express the solubility behavior 
of a system with interacting components forming soluble complexes, the following mass 
action equations are used. These equations are derived assuming 1:1 complex formation. 
 Suppose that a single complex, XY, is responsible for the increase in the apparent 
solubility of X. The equation representing this reaction can be expressed as: 
aqaq YX  ⇄ XYaq             (1.1) 
 
   aqaq
aq
YX
XY
K               (1.2) 
The concentrations can then be expressed in terms of known quantities as follows: 
   0XX aq                (1.3) 
     0XXXY taq               (1.4) 
     aqtaq XYYY               (1.5) 
where 0X  is the equilibrium solubility of X in the absence of Y, tX  is the total 
concentration of dissolved X regardless of the molecular state, and tY  is the total added 
concentration of Y. Type AP phase diagrams may represent the formation of two 
complexes, XY and 2XY ,characterized by the following constants: 
 
  YX
XY
K 1:1               (1.6) 
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 
  YXY
XY
K 22:1               (1.7) 
(b) Type B diagrams 
 Type B diagrams (Figure 1.4) are observed when insoluble complexes are 
formed. In curve Bs (Figure 1.4), from point X0 to point a, the apparent solubility of X 
increases because of soluble complex formation between X and Y. At point a, the 
solubility of the complex is reached. Adding more Y causes more complex formation, 
which precipitates keeping the concentration of uncomplexed X constant. At point b, 
entire solid X is converted to a complex, and adding more Y results in the depletion of X 
in the solution through complex formation and concomitant precipitation of the insoluble 
complex. The curve Bl  can be understood in the same manner, except that the complex 
formed is so insoluble that the initial rise in the concentration of X is undetectable. These 
diagrams may sometimes show an increase in solubility beyond point c, apparently due to 
the formation of another complex species that is more soluble than the one responsible 
for the descending portion of curve b-c.  
 
13 
 
Figure 1.4. Phase solubility diagram of Type B systems. Adapted from Higuchi and Connors.10  
  
1.2.2 Dissolution Model for Binary Mixtures of Non-Interacting Components 
 When a uniform, non-disintegrating, intimate mixture of two crystalline 
components, A and B, is exposed to a solvent, both components begin to dissolve at rates 
proportional to their solubilities and diffusion coefficients, according to the Noyes-
Whitney equation (Equation 1.8): 
)( bs CC
h
DS
dt
dW
              (1.8) 
where dtdW /  is the dissolution rate, D is the diffusion coefficient, S is the effective 
surface area and h is the hydrodynamic boundary layer thickness, sC  is the saturation 
solubility, and bC  is the instantaneous concentration in the bulk solution at time t . 
Initially, the dissolution rate (R) of components A and B from a compact of constant 
surface area under sink conditions can be expressed as: 
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h
CD
R AAA
0
               (1.9) 
h
CD
R BBB
0
             (1.10) 
where AD and BD are the diffusion coefficients of components A and B, respectively, and 
0
AC and 
0
BC are the saturation solubilities of components A and B, respectively. 
 After a short period, usually one of the components becomes depleted in the solid-liquid 
interface of the solid compact. This occurs when 
B
A
N
N
is not equal to 
0
0
BB
AA
CD
CD
, where NA 
and NB represent the amount of A and B in the compact respectively. Consequently, a 
surface layer is formed made up of only one of the components. Therefore, at t > 0, one 
of the following cases as shown in Figure 1.5 can exist: 
 
 
 
 
 
            Case 1                                            Case 2                                               Case 3 
 
Figure 1.5. Dissolution of two-component solids. Case 1: critical mixture composition where A 
and B coexist at the compact surface; Case 2: component A dissolves quickly to leave a layer of 
component B at the compact surface; Case 3: component B dissolves quickly to leave a layer of 
component A at the compact surface. 
 
Case 1 (Critical mixture composition): Here, components A and B coexist at the solid-
liquid interface. This occurs when the following condition (Equation 1.11) is met: 
A 
+  
B 
B A 
A 
+  
B 
A 
+  
B 
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0
0
BB
AA
B
A
CD
CD
N
N
             (1.11) 
In this case the dissolution rates of components A and B can be determined using 
Equations 1.9 and 1.10, respectively. 
Case 2: This case arises when the mass fraction of B in the solid compact is higher than 
its rate of dissolution, such that a porous layer of B is formed on the compact surface. 
This condition is represented by the following equation (Equation 1.12): 
0
0
BB
A
B
A
CD
CAD
N
N
             (1.12) 
The dissolution rate of component B can be determined using Equation 1.10 whereas 
that of component A can be calculated from Equation 1.13: 
B
B
A
A R
N
N
R              (1.13) 
     
Case 3: This situation case arises when the mass fraction of A in the solid compact is 
higher than its rate of dissolution, such that a porous layer of A is formed on the compact 
surface. This condition is represented by the following Equation 1.14: 
0
0
BB
AA
B
A
CD
CD
N
N
             (1.14)  
The dissolution rate of component A can be determined using Equation 1.9 whereas that 
of component B can be calculated from Equation 1.15: 
A
A
B
B R
N
N
R              (1.15) 
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 The dissolution model for binary mixtures of non-interacting components is based 
on two main assumptions. The first is the steady-state approximation. The equations 
describing dissolution rate of each component from binary mixtures are applicable only 
after the surface layer of component B or A is formed on the solid compact (Case 2 and 
Case 3, respectively). If the two components have comparable solubilities (less than an 
order of magnitude), then the time required to reach steady-state is short. The other 
assumption, when deriving the aforementioned equations, is that the porous surface 
layers do not change in any substantive manner, other than they enlarge during 
dissolution. In other words, the porosity of the growing surface layer does not change as 
dissolution proceeds. 
 Shah et al. applied the equations for dissolution rates, described earlier, to aspirin-
salicylic acid mixtures and phenacetin-caffeine mixtures of various compositions. The 
experimental dissolution rates were determined and compared with the theoretical values. 
The experimentally measured dissolution rates were in good accordance with the 
theoretically predicted rates. The results obtained with solid mixtures prepared using the 
melt method deviated lesser from theory than those prepared using compression, because 
of a more intimate mixing of components in the melt preparations. An increased content 
of caffeine in phenacetin-caffeine mixtures led to deviations of the experimental 
dissolution rates from those theoretically calculated. This was attributed to the high 
solubility of caffeine that caused flaking and an increase in effective surface area of the 
compact.11, 12 Therefore, the equations developed by Higuchi et al. for calculation of the 
dissolution rate of each component from a binary mixture can be suitably applied to 
compacts containing two materials, such as two drugs or a drug-excipient mixture.  
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1.2.3 Dissolution Model for Binary Mixtures of Interacting Components 
 Higuchi et al. developed a model to predict the dissolution rate of mixtures of 
components that interact in solution to form soluble complexes. Assuming that the only 
interaction involves a solution reaction represented by: ABBA  , the equilibrium 
constant of this reaction can be written as: 
BA
AB
CC
C
K              (1.16) 
where 
AC , BC , and ABC are the concentrations of components A, B, and AB complex, 
respectively. When phase A dissolves slower than phase B (Figure 1.5, Case 3), leaving 
a layer of solid depleted of B, the dissolution rate of A ( AR ) at a steady state, can be 
written as:  
dX
dC
D
dX
dC
DR ABAB
A
AA            (1.17)  
where AD and ABD  are the diffusion coefficients for unbound A and the complex, 
respectively and X is the spatial coordinate in the direction of diffusion in the liquid 
diffusion layer. Accordingly the dissolution of component B can be written as: 
dX
dC
D
dX
dC
DR ABAB
B
BB            (1.18) 
Equations 1.17 and 1.18 may be integrated over the limits with boundary conditions: 
At X = 0 (solid–liquid interface) of the solid compact: 
0
AA CC  ,

 BB CC and 

 ABAB CC  
At X = h (the bulk solution): 
0 ABBA CCC  
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where 
0
AC is the equilibrium solubility of A, and 

BC and 

ABC are the concentrations of 
free B and the complex at the solid-solution interface. Integration of Equations 1.17 and 
1.18, leads to the following pair of equations: 

 ABABAAA CDCDhR
0
          (1.19) 



 ABABBBB CDCDhR           (1.20) 
At steady state, Equation 1.21 holds: 
B
B
A
A R
N
N
R                         (1.21) 
Solving Equations 1.16, 1.19–1.21 results in the following: 
)(
1
0
0
0
AABBA
AABB
AA
A
KCDDN
KCDN
CD
hR


          (1.22) 
0
0
0
AABB
AAB
B
A
AA
B
KCDD
KCD
N
N
CD
hR


                      (1.23) 
 Similarly when pure B is the surface phase, the dissolution rates of the 
components can be calculated using the following equations: 
)(
1
0
0
0
BABBB
BABA
BB
B
KCDDN
KCDN
CD
hR


          (1.24) 
0
0
0
BABA
BAB
A
B
BB
A
KCDD
KCD
N
N
CD
hR


          (1.25) 
For the critical mixture case: 
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X = 0, 
0
AA CC  and 
0
BB CC   
X = h, 0 BA CC  
Therefore, 
000
ABABAAA CKCDCDhR            (1.26) 
000
ABABBBB CKCDCDhR            (1.27)  
 Shah et al. applied these equations to binary mixtures of aspirin and caffeine and 
Higuchi et al. applied it to benzocaine-caffeine mixtures. Both studies indicated that the 
theory suitably agreed with experimental observations. Deviations were attributed to the 
assumption of a 1:1 complex in the derivation of the equations.12 
1.3 Background to Dissolution Rate-Limited Oral Bioavailability 
The number of poorly water-soluble drug candidates in contemporary 
pharmaceutical pipelines has recently increased, and this has been largely attributed to 
the use of combinatorial chemistry and high-throughput screening assays in drug 
discovery.13-16At present, approximately 70 % new drug candidates and approximately  
40 % marketed immediate-release drugs exhibit poor aqueous solubility, posing a hurdle 
for formulation scientists working on oral delivery. Several problems arise from the poor 
solubility of drug candidates in research and development. The aqueous solubility of a 
drug is a critical determinant of its dissolution rate. The limited dissolution rate arising 
from low solubility frequently results in poor bioavailability of orally administered drugs. 
This is particularly important for Biopharmaceutics Classification System (BCS) Class II 
drugs (low solubility, high membrane permeability) and BCS Class IV drugs (low 
solubility, low membrane permeability).14, 17 In such cases, high drug doses are generally 
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given to achieve therapeutic drug concentrations. However, administering large doses can 
result in toxicity and poor patient compliance making it imperative to develop 
formulation strategies for dissolution rate enhancement. The drug concentration in the 
gastrointestinal tract is determined by the dissolution rate, whereas the upper limit is its 
solubility. Therefore, the oral absorption of BCS Class II drugs can be solubility-limited 
or dissolution rate-limited. Solubility-limited absorption occurs when the dose to 
solubility ratio (defined as the volume of gastrointestinal fluids required to dissolve the 
administered dose) is high. In this case, the maximum achievable concentration limits 
absorption such that, neither an increased dose nor particle size reduction improves oral 
bioavailability. The concept of solution supersaturation using high energy solid forms, 
such as metastable polymorphs or amorphous solid forms, solubilized formulations and 
solid dispersions is commonly used to overcome solubility-limited bioavailability. 
Dissolution rate-limited bioavailability occurs when the drug dose is soluble, but the time 
required to dissolve it is greater than the time required for gastrointestinal transit. 
Dissolution rate limitations can be overcome by an increased dose, particle size 
reduction, or increased solubility.18, 19-21 Several methods are available to increase the 
dissolution rate, which can be understood by considering the Noyes-Whitney equation as 
explained below.  
 Noyes and Whitney studied the dissolution of two sparingly soluble compounds, 
benzoic acid and lead chloride by maintaining a constant surface area.22 The dissolution 
rate (mass dissolved per unit of time) was proportional to the difference between the 
instantaneous concentration, Cb, at time t and the saturation solubility, Cs, according to 
the following equation: 
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)( bs CCk
dt
dW
                      (1.28) 
where dW/dt is the dissolution rate, and k is a constant. Nernst and Brunner modified this 
equation to incorporate the diffusion layer concept and Fick’s second law of diffusion 
and obtained Equation 1.8 (Section 1.2.2). It was assumed that drug diffusion across a 
stagnant diffusion layer was the rate-limiting step in dissolution.23 Based on this analysis, 
the main possibilities of improving dissolution rate are to increase the surface area, 
enhance wetting of the solid, decrease the boundary layer thickness, ensure sink 
conditions during dissolution, and improve the solubility of the drug.23, 24 Changes in  
in vivo hydrodynamics are difficult to impose and the maintenance of sink conditions 
depends on drug permeability and the gastrointestinal fluid volume available. Therefore, 
the major factors that can be altered to improve dissolution rate are solubility and surface 
area. Solubility is dependent on the crystal lattice energy and the affinity of the solute for 
the solvent. Therefore, reduced intermolecular interaction in the solid-state and an 
increased strength of solute-solvent interaction results in an improved dissolution  
rate.24, 25 Furthermore, an increase in the surface area of the solid drug available for 
dissolution by particle size reduction can also increase dissolution rate. These approaches 
are discussed in the next section. 
1.3.1 Formulation Strategies for Dissolution Rate Enhancement 
1.3.1.1 Solubility Modification 
 Solubility, is a key factor in the modified Noyes–Whitney equation (Equation 
1.8), as combined with the already dissolved drug concentration and the boundary layer 
thickness it is used to determine the concentration gradient across the boundary layer, 
which is the driving force for dissolution. Several factors influence drug solubility in the 
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gastrointestinal tract, such as the solid form of the drug, pKa of the drug (or salt form) and 
solubilization by native surfactants. However, formulation strategies for solubility 
modification most commonly involve using metastable polymorphs or amorphous solid 
form of the drug; developing salt forms and soluble prodrugs, and crystal engineering 
approaches such as co-crystals; and using solubility enhancing excipients such as 
cyclodextrins. 
 Crystalline solids that differ only by the arrangement and packing of drug 
molecules in the crystal lattice are known as polymorphs. Polymorphs differ in free 
energy and exhibit different physicochemical properties such as density, melting point, 
solubility, and stability.25 Solubility differences between polymorphs are due to 
differences in crystal lattice energy; such that metastable polymorphs with lower lattice 
energies have higher solubility than thermodynamically stable crystal forms. The 
solubility difference between polymorphs is typically less than two-fold, although 
occasionally higher ratios have been observed.26, 27 For example, the solubility ratio of 
tolbutamide polymorphs (IV/II) and polymorph (I/II) was 1.5 and 1.1, respectively.27 
Further increase in solubility can be obtained using the amorphous form of the drug, that 
lacks the long-range order of molecular packing, unlike its crystalline counterpart. The 
difference in solubility between the amorphous and the crystalline form has been reported 
to be between 1.1to 1000 fold.27 The marked enhancement in the solubility of an 
amorphous drug may lead to a significant improvement of oral bioavailability. Although 
the use of high-energy solid forms is an effective approach to increase solubility and 
thereby dissolution rate, these forms have the ability to convert to the thermodynamically 
stable crystalline form with a lower solubility, making it necessary to monitor the 
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possibility of any transformation during manufacturing, storage, and dissolution testing. 
Creating amorphous solid dispersions (ASD) with suitable polymeric excipients and 
surfactants is a widely used technique to stabilize the amorphous state of the drug and 
lower the propensity of phase transformation to the crystalline form. Amorphous solid 
dispersions facilitate in stabilizing the amorphous drug by physically intercalating the 
drug molecules between the side chains of the polymeric carrier, thereby reducing 
molecular mobility and lowering the tendency for recrystallization.28, 29 Drug 
maintenance in the amorphous state, local increases in solubility and wettability, and 
increase in the surface area as the carrier dissolves contribute to dissolution rate 
enhancement from an ASD. An amorphous solid dispersion (ASD) of ER-34122 (a novel 
5-lipooxygenase/cyclooxygenase inhibitor) showed an approximate 100-fold increase in 
Cmax and AUC compared to the pure drug, when administered orally to beagle dogs.
30 
 The salt formation approach is widely used to increase the solubility of ionizable 
drugs due to interactions of charged ions with solvent molecules. Changes in pH at the 
surface of the dissolving salt particle results in a higher dissolution rate of salts compared 
to free forms.31 In one study, the mesylate salt of LY333531 (a potent protein kinase 
inhibitor) had a 2.6 times higher Cmax and AUC in dogs than that with an equivalent dose 
of the hydrochloride salt.32Crystal engineering approaches such as the use of co-crystals 
is also a popular method for increasing dissolution rate. Co-crystals are crystalline solids 
containing multiple components held together by noncovalent intermolecular forces.33, 34 
Co-crystals of AMG 517 (a potent and selective VR1 antagonist) with sorbic acid showed 
a higher dissolution rate in a fasted state simulated intestinal fluid and a 9.4-fold higher 
AUC compared to the free base form of the drug when administered to dogs.34 
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 Soluble prodrugs have been used to overcome the solubility limitation of poorly 
soluble drugs. The two main strategies to produce soluble prodrugs are derivatization 
with a promoiety designed to decrease the drugs melting point and/or introduction of an 
ionizable functional group.35 A phosphate ester prodrug (Etopofos) of etoposide showed a 
10-fold increase in Cmax compared to etoposide and an AUC twice that of the parent drug 
when administered orally to rats.36, 37 This approach is valuable because the phosphate 
prodrug is converted to etoposide within 5 min in plasma. 
 Although the approaches previously described are widely used to enhance 
dissolution rate, there are limitations to the use of these techniques. For example, salt 
formation is not applicable for neutral compounds and even when salts are formed, a risk 
of the reconversion of the salt to the poorly soluble free form, during dissolution exists.31 
High solubility of metastable polymorphs and amorphous solids makes their use in 
dissolution rate enhancement popular. However, there is a risk of transformation of a 
“high-energy” solid form to the stable crystalline form during storage and dissolution. 
This can result in variable bioavailability of formulations containing metastable solid 
forms. Furthermore, the commercial use of amorphous solid dispersions has been limited 
because of manufacturing and handling difficulties, making dosage form development 
and scale-up challenging. Physical instability, such as drug crystallization in dispersions 
during storage is also a major problem limiting their use.29 In addition, the safety and 
toxicity of co-crystal forming agents are serious drawbacks to their widespread utility.25 
 Particle size reduction is an attractive option for dissolution rate enhancement 
because it is applicable to drugs regardless of their chemical characteristics. The next 
sections (Sections 1.3.1.2 and 1.3.1.3) describe the mechanism of dissolution rate 
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enhancement achieved by size reduction, methods to achieve size reduction, and 
problems associated with these methods. 
1.3.1.2 Particle Size Reduction 
 Particle size reduction leads to an increased surface area available for solvation 
and thereby, an increase in dissolution rate based on the modified Noyes-Whitney 
equation (Equation 1.8). Based on the inverse relationship between particle size and 
specific surface area (SSA), drug micronization and nano-sizing techniques have been 
widely used to improve the oral bioavailability of poorly soluble drugs. However, the 
effects of particle size reduction in increasing dissolution rate cannot be solely explained 
by the increase in surface area. According to the Prandtl boundary layer equation 
(Equation 1.29), a decrease in particle size (below 2 µm) results in a thinner 
hydrodynamic layer (
Dh ) around the particles, which is attributed to their increased 
curvature, thereby resulting in an increase in dissolution rate.38-41  
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where k is a constant, L is the particle length on which liquid flows at constant velocity 
and V is the velocity of fluid flow. 
 An increase in the dissolution rate upon nano-sizing (particle size < 1 µm) may 
also be attributed to increased saturation solubility, as explained using the Ostwald-
Freundlich equation (Equation 1.30): 
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where S is the solubility of the nanosized API, S∞ is the saturation solubility of an 
infinitely large API crystal or a plane surface, γ is the crystal-medium interfacial tension, 
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M is the molecular weight, r is the particle radius, ρ is the density of the crystal, R is the 
gas constant, and T is the absolute temperature.42-45 The Ostwald-Freundlich equation is 
derived from the Kelvin equation, according to which the vapor pressure of liquid 
droplets in the gas phase increases with increasing curvature of the surface, implying a 
decreasing particle size. In addition to the effects of particle curvature on size reduction, 
milling techniques used for micronization and nano-sizing can cause small defects in the 
crystal lattice particularly on the particle surface, which weaken the solute-solute 
interactions in the lattice, resulting in an increased apparent solubility.46, 47 
 Particle size manipulation may be obtained using either “top-down” processes, 
where large particles are fragmented into small particles, or using “bottom-up” processes 
in which small particles are harvested after drug recrystallization from a supersaturated 
solution. Top-down processes are usually dry impact methods that introduce considerable 
shear forces and reduce the particle size of coarse drug powders, using ball mills, hammer 
mills, and air-jet mills. However, some powder materials are prone to phase 
transformation upon dry milling. Further the heat generated upon attrition may not be 
suitable for low melting point drugs or thermolabile materials.48-50 Alternatively, top-
down wet milling methods, such as pearl milling, can produce particles in the nanometer 
range. In this method, an aqueous drug slurry with surfactants and/or polymers is stirred 
with hard milling beads.51-53 High-pressure homogenization is another wet milling 
method used to produce nanoparticles.54, 55  
 Bottom up approaches for particle size reduction and nanosizing involve 
controlled precipitation or crystallization of the drug from a supersaturated solution. The 
first step involves creating a supersaturated solution followed by nucleation and crystal 
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growth; therefore, the success of this approach is dependent on a high supersaturation 
level. Sonication is usually applied to prevent crystal growth and particle agglomeration, 
and results in production of particles with a narrow size distribution.55-56  
 Based on the increase in SSA and consequently increased dissolution rate, after 
particle size reduction, several studies have used micronizing and nanosizing of poorly 
soluble drugs in an attempt to improve oral bioavailability. In one study, cilostazol (an 
antiplatelet agent) suspensions with different particle size distributions were prepared 
using hammer-milled crystals (d50 13 µm), jet-milled crystals (d50 2.4 µm), and 
NanoCrystal® spray-dried powder (d50 0.22 µm). This study showed a significant effect 
of particle size reduction on dissolution rate. Approximately 45 % of the drug was 
dissolved in 60 min from the hammer-milled suspension, 80 % was dissolved within  
15 min from the jet-milled suspension, and an almost instantaneous dissolution was 
observed from the spray-dried powder. In vivo studies in beagle dogs indicated that the 
AUC of the spray-dried suspension was 6-fold higher than that from the other 
suspensions.57 In another study, aprepitant powder was reduced in size from 5.5 µm to 
120 nm using a wet-media milling method. Compared to the micronized particles, the 
surface area of the nanoparticles increased 42-fold and AUC0-72h increased 4-fold when 
administered orally to beagle dogs.58 
1.3.1.3 Negating Particle Size Reduction: Agglomeration Problem 
 Although particle size reduction resulting in surface area increase is a commonly 
used approach to enhance dissolution rate, in some cases reduced rates have been 
reported. This has been attributed to the agglomeration of micronized particles. It is well 
established that fine particles (< 100 µm) are cohesive and tend to agglomerate as the 
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magnitude of inter-particle forces exceeds the particle weight.59 Several forces are 
responsible for particle agglomeration as discussed below: 
Van der Waals forces: These forces occur because of electron movement to form dipoles, 
which in turn are attracted to other dipoles nearby and are significant at inter-particle 
distances of 0.2–1 nm. The van der Waals force ( vdwF ) between two smooth spheres is 
given by: 
212d
AR
Fvdw              (1.31) 
where A is the Hamaker constant of the material, R is the radius of curvature of a two 
particle system, and d is the distance between the spheres.60-63 This force is proportional 
to the particle diameter compared to the gravitational force, which is proportional to the 
cube of the particle diameter. Therefore, van der Waals forces become negligible, relative 
to gravitational forces, in systems where the particle diameter exceeds a certain value of 
the order of a few microns. The van der Waals force between a sphere (1) in contact with 
a flat surface (2) is larger in magnitude than that between two spheres of the same radius 
and is given by the following equation: 
26d
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 Contact area, surface roughness, and radii of asperities also affect the magnitude 
of this force. Surface roughness can cause a reduction in the area of contact on which van 
der Waals forces act. The effects of surface roughness on force are dependent on the 
nature of the roughness. Consider a system of two particles; if surface asperities on the 
surface of one of the particles are smaller than the diameter of the other particle, then the 
contact area is reduced resulting in a decrease in the magnitude of the van der Waals 
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forces between the particles. The situation is reversed when the asperities are larger than 
the other particle. This concept is illustrated in Figure 1.6.60, 61  
 
 
 
 
Figure 1.6. Effects of surface roughness on contact area: (a) asperities smaller than particle size;  
(b) asperities larger than particle size. 
 
Electrostatic forces: Contact between particles of different materials or particles with 
equipment surfaces causes’ electron exchange. Because most pharmaceutical powders are 
electrical insulators, electron accumulation on particle surfaces causes the particles to 
remain charged even after separation (triboelectric charging). The force acting between 
two particles with charges q1and q2 is expressed as: 
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where ε0  is the vacuum permittivity and d is the distance between the particles. 
Electrostatic forces may be several orders of magnitude smaller than van der Waals 
forces particularly at higher relative humidities.60, 62 
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Capillary forces: This force develops because of capillary condensation of water at the 
points of contact between particles at higher relative humidities (65–80 %). The capillary 
force ( cF ) between a spherical particle (1) and a flat surface (2) can be calculated as: 
)cos(cos2 21   rFc         (1.34) 
where r is the radius of the particle, 1 and 2 are the contact angles between the two 
bodies in contact with a liquid and  is the surface tension of the liquid. Various factors 
such as surface roughness and particle wettability influence the magnitude of this force.62 
 Various factors such as particle size, inter-particle distance, and atmospheric 
humidity determine the magnitude of inter-particle forces. In general, a very short acting 
range of these forces make them less significant as the inter-particle distance increases.  
 Agglomeration of micronized particles causes a fraction of the particles’ surface 
area being enclosed within the agglomerates and unavailable for dissolution. This causes 
the effective surface area term in the modified Noyes-Whitney equation (Equation 1.8) 
to be considerably lower than the total surface area of the drug particles. The 
agglomeration effect along with the poor wettability of hydrophobic drug surfaces causes 
a smaller increase in dissolution rate than that theoretically expected from the specific 
surface area of the solid. 
 Crison et al. studied the dissolution profile of two particle size fractions of a 
poorly soluble drug: the bulk drug with an average diameter of 29 µm (±2.1 µm) and 
micronized drug particles with an average diameter of 4 µm (±1.6 µm). They observed 
that the dissolution rate from the micronized particles was significantly lower than that 
predicted using the Hixson-Crowell cube root equation. This observation was attributed 
to the re-agglomeration of micronized particles which was confirmed by optical 
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microscopy.64 Similar effects of agglomeration on the dissolution rate was also observed 
in a study involving cefuroxime axetil nanoparticles.65 
 Another example of agglomeration behavior was observed in nifedipine 
dissolution. The percent drug dissolved at 30 min (Q30) for several size fractions with  
d99 values of 233.23±18.82 µm (N1), 36.79±1.31 µm (N2), and 29.94±4.70 µm (N3) 
were compared. The Q30 values increased from 13.9±2.9% to 23.1±2.7% with a decrease 
in d99 from 233.23 m to 36.79 m. However, further size reduction decreased the Q30 
value to 18.8±1.8% for N3. This decrease was caused by the agglomeration of the smaller 
size N3 particles, resulting in low effective surface area and dissolved amount.64 
1.4 Interactive Mixtures for Dissolution Rate Enhancement 
1.4.1 Concept 
 When the difference in particle size between two components is sufficiently large 
(one or two orders of magnitude), the small particles tend to adhere to the larger particles 
because the inter-particle adhesion force between these two particles exceeds the weight 
of the smaller particle.59, 61, 66-68 Hersey coined the term “ordered mixtures” to describe 
mixtures that are expected to result from the adherence of fine particles of one constituent 
to the considerably coarser particles (carrier particles) of a second constituent.69 The term 
“interactive mixtures” used by Egermann described these mixtures more appropriately, 
because adhesion is fundamentally a mechanism of interaction and not of order. Ordered 
systems can only be achieved when an identical (or almost identical) number of 
monosized fine particles (usually drug particles) adhere to each carrier particle producing 
mixtures having a higher degree of homogeneity than random mixtures.64-70 Therefore, 
the term “interactive,” which has no relation to the actual degree of homogeneity 
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achieved, is used throughout this dissertation to describe mixtures consisting of fine 
particles adhered to coarse carriers.70-72 Interactive mixtures have been used in the 
pharmaceutical industry to minimize segregation, and improve flow and tableting 
properties and dissolution rates of poorly soluble drugs.67, 73, 74 
 Interactive mixture formation occurs in three steps shown in Figure 1.7.67, 75 The 
first step in this process involves breakdown of agglomerated micronized drug particles 
into smaller agglomerates or primary drug particles. Agglomerate breakdown occurs 
when the carrier particles impact the agglomerates during the mixing process. The high 
ratio of carrier material to drug leads to a large carrier surface available to interact with 
drug particles. In the next step (Step 2), the carrier and drug particles collide resulting in 
the bonding of the drug particles with the carrier surface. Because of the large size 
differences between the fine drug particles and the coarse carrier particles, the inter-
particle contact can be approximated as a sphere (drug particle) in contact with a flat 
surface (carrier particle). A larger magnitude of van der Waals force between a sphere 
and flat surface (Equation 1.32) than that between two spheres of the same size 
(Equation 1.31) is responsible for keeping the drug particles adhered to the carrier 
surface. Other inter-particle adhesive forces include capillary and electrostatic forces. 
Finally, redistribution and exchange of the drug particles among the carrier particles 
occurs after a uniform mixture is formed (Step 3).63 
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Figure 1.7. Schematic representation of steps involved in the interactive mixing process: pink-
carrier particles; blue-micronized drug particles. 
1.4.2 Methods of Preparation of Interactive Mixtures 
 Mechanically stable interactive mixtures are formed when the adhesive force 
between the coarse carrier particles and the micronized drug particles is greater than the 
cohesive force for either component. This is essential for the micronized drug particles to 
adhere to the carrier surface.72 Some methods used to achieve this are discussed below. 
Dry mixing: This process involves impaction and collision of the carrier particles with the 
agglomerates of the micronized drug particles. Tumbling mixers such as V-blenders, 
Turbula mixers, and cube mixers are used for this purpose. This method is commonly 
used to produce interactive mixtures because of its simplicity and the absence of shear 
forces that might affect thermolabile drugs or fragment carrier particles.74, 75 
Triboelectrification: Pharmaceutical powders are prone to electrostatic charging known 
as triboelectrification by colliding and sliding contacts with equipment walls and other 
particles. Electron transfer occurs between the components, and the high resistivity of 
pharmaceutical materials prevents the transferred charge from leaking back. Therefore, 
these materials acquire a positive or negative charge depending on their electronic 
properties.76, 77 This phenomenon can be used to form interactive mixtures. In this case, 
carrier and drug particles can be given opposite charges through triboelectrification, 
which reduces cohesion and enhances adhesion. In one study, fine potassium chloride 
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particles coated with positively charged polymers adhered to negatively charged sugar 
particles. The segregation tendency of the triboelectrified powder mixtures was less than 
conventional mixtures.77 
Dry impact blending: In this method, large impulsive forces are used to firmly attach the 
fine particles on the carrier particles, for example, Mechanofusion® and Hybridizer® 
equipment. The Mechanofusion® equipment uses compression and frictional forces to 
cause surface fusion and embedment of the fine particles on the carrier surface.74, 78 
Magnetically assisted impaction coating (MAIC): A magnetic field is used to accelerate 
and spin magnetic particles mixed in with fine drug and coarse carrier particles 
promoting collisions between them and leading to embedment of fine particles on the 
carrier. This method has been used to coat cornstarch with fine silica particles to improve 
flowability.79 
Adhesion and coating: In these methods, binders and/or granulating agents may be used 
to enhance the adhesion between the micronized drug and carrier particles, thereby 
improving the mechanical stability of the mixtures. Supercritical fluid-based coating 
techniques and deposition of drug particles dispersed in a solvent on carriers are also 
used.80-82 
 The dry mixing method has been most commonly used for preparation of 
interactive mixtures for dissolution rate enhancement. This is because all the other 
methods described result in the formation of relatively strong adhesive forces between the 
components. An important prerequisite for dissolution rate enhancement involves 
detachment of drug particles from the carrier surface, making the dry mixing method the 
most suitable method for dissolution rate enhancement. 
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1.4.3 Mechanism of Dissolution Rate Enhancement of Interactive Mixtures 
 Most of the inter-particle forces responsible for interactive mixture formation 
have reduced magnitude in liquid media as discussed below. This is important for 
releasing dispersed drug particles (or small clusters) from the carrier surface. Once the 
particles are released from the carrier, enhanced wetting and large effective surface area 
causes faster dissolution. 
 Van der Waals forces are the dominant interaction forces between particles 
comprising an interactive mixture, and operate both in vacuum and in liquid 
environments, although in the latter case the force is considerably reduced.83, 84  Van der 
Waals interaction force between a sphere of radius R (1) and flat surface (2) is given by 
Equation 1.32 (Section 1.3.1.3), where the Hamaker coefficient A12 between the two 
components can be obtained to a good approximation by: 
221112 AAA              (1.35) 
where A11 and A22 are the individual coefficients in a vacuum or gas environment. For a 
three-component system, namely two materials (1 and 2) in a liquid environment (3), the 
coefficient is written as: 
     (1.36) 
 
 It is possible for the coefficient to attain a negative value, or give conditions 
where the van der Waals force is negative, such as when A132 <0, or when A11 < A33< 
A22.
82, 83 Consequently, immersion in water leads to a substantial reduction in Fvdw. Lower 
the individual value of the coefficient of the material, greater is the reduction in the 
magnitude of this force. 
))(( 33223311132 AAAAA 
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 Electrostatic forces also have considerably reduced magnitude in a liquid 
environment. The dielectric constant of water (80.4) is much larger than that of air (~1), 
causing a reduction in the magnitude of electrostatic forces.82, 84 
 Capillary forces arise from the condensation of atmospheric moisture as a 
meniscus between the particles and air. Assuming that the solid particle surface is wet 
because of water, this meniscus disappears, such that capillary forces are not relevant in 
liquid media.83, 85 
 Interactive mixtures are made using the dry mixing process where the coarse 
carrier particles help to effectively deagglomerate and disperse agglomerates of the 
micronized drug into dispersed drug particles or small clusters. These drug particles then 
adhere to the carrier surface (Figure 1.7). As discussed previously, the magnitude of 
inter-particle forces between micronized drug and carrier particles decreases in liquid 
media. This can facilitate the detachment of adhered drug particles from the carrier 
surface. Because the drug agglomerates are broken down into dispersed drug particles or 
smaller agglomerates, it is expected that after the dissolution of the soluble carrier or the 
displacement of the drug particles from the hydrophilic carrier surface, a larger surface 
area of the drug will be exposed to the solvent. These processes lead to dissolution rate 
enhancement. 
 The hydrodynamics of an agitated system of suspended particles can be used to 
explain the increase in the dissolution rate obtained using interactive mixing. Solids 
dispersed in liquid media, under agitation, are surrounded by zones of less movable 
liquids (boundary layers) reflecting a velocity gradient between the bulk fluid and the 
solid surface. From the Prandtl equation (Equation 1.29, Section 1.3.1.2), it is clear that 
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a decrease in particle size corresponds to a reduced distance on which frictional forces 
can act, leading to a thinner velocity gradient. This corresponds to a short diffusional 
distance (hD) where liquid motion is almost absent and diffusion dominates. In case of 
interactive mixtures, the carrier particle initially determines the hydrodynamic conditions 
and large values for particle length on which liquid flow L and consequently hD are 
obtained. When the carrier particle dissolves and drug particles are released, the fluid 
around each drug particle has a high velocity (V) combined with a low particle size (low 
L) resulting in a smaller value of hD. Thus, when deagglomerated drug particles are 
released from the dissolving carriers, it is suggested that the reduced diffusional distance 
results in rapid dissolution process comparable with well-dispersed suspension system.38 
In one study, the drug surface area participating in dissolution was calculated and was 
found to be in agreement with the external surface area of the primary particles 
(determined by permeametry).33 
 Figure 1.8 depicts the dissolution processes from physical and interactive 
mixtures. After interactive mixing, the drug agglomerates are broken down into dispersed 
particles and smaller agglomerates. The large effective surface area of the drug particles 
from interactive mixtures is responsible for dissolution rate enhancement. For physical 
mixtures, the drug agglomerates are not effectively deagglomerated, causing a large 
fraction of the drugs’ surface area to be enclosed in the agglomerate structure. The lower 
effective surface area of the drug particles in physical mixtures is responsible for slower 
drug dissolution from these mixtures than that from interactive mixtures.  
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Figure 1.8. Schematic representation of dissolution process from interactive and physical 
mixtures: pink-carrier particles; blue-micronized drug particles. 
 
1.4.4 Factors affecting Dissolution Rate Enhancement from Interactive Mixtures 
Surface coverage 
 The amount of drug that can be incorporated into interactive mixtures is limited 
by the surface area of the carrier particles. The surface area ratio (Rs), which is based on 
the ratio of projected area of drug particles and the external surface area of the carrier 
particles, is used to describe the degree of surface coverage of the carrier. In general, the 
dissolution rate decreases with an increasing surface coverage (Rs) value. It is assumed 
that at high surface coverage, a film of hydrophobic drug particles formed around the 
carrier impedes carrier dissolution and the release of drug particles from the carrier 
surface. Because carrier dissolution is crucial to release the drug as dispersed particles, 
high degrees of surface coverage are typically associated with slower dissolution rates. In 
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addition, an increase in carrier surface coverage is linked to the incomplete 
deagglomeration of the drug, leading to reduced dissolution rates. The effects of surface 
coverage of two micronized drugs, griseofulvin and oxazepam, with lactose and mannitol 
carriers on the dissolution rate was studied by Nilsson et al.86-89 The authors observed 
that oxazepam mixtures, with the lowest Rs, exhibited the highest dissolution rates. The 
results were expressed as a percentage of the maximum dissolution rate (kM), which was 
calculated from the knowledge of the intrinsic dissolution rate and surface area of the 
drug particles. For griseofulvin-lactose mixtures with Rs values 0.5 and 1, the dissolution 
rates were 69 % and 46 % of kM, respectively. For the highest surface area ratio of 
griseofulvin corresponding to the Rs value 1, tablets showed a higher dissolution rate of 
72 % of kM than the uncompressed mixture. This was attributed to the fracture of carrier 
particles, when the tablet was formed.86 Although a high degree of surface coverage is 
associated with slower dissolution rates, Westerberg et al. demonstrated that interactive 
mixtures dissolved rapidly even when the surface coverage was high.89 This anomalous 
result was attributed to the uncertainty in estimating the coating capacity of the carrier. 
As explained earlier, the surface coverage was determined based on external surface area 
measurements by microscopy. In case of carrier particles with morphologies deviating 
from spherical geometry, a large amount of drug was necessary to achieve complete 
coverage resulting in the unexpected outcome of this study. 
Mixing time 
 Mixing time is an important parameter that affects the rate of drug dissolution 
from interactive mixtures. Selecting an optimal mixing time is necessary because 
insufficient mixing can cause incomplete break down of the drug agglomerates. 
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Westerberg et al. showed that an increase in mixing time produced an increase in the 
dissolution rate of oxazepam-mannitol mixtures with 100 % surface coverage.86 Greater 
increase in dissolution rate following longer mixing time was attributed to increased 
degglomeration and consequent high effective surface area of the drug available for 
dissolution. Conversely in some studies, longer mixing times were associated with 
overcoating the carrier with hydrophobic drug particles. The inability of the solvent to 
penetrate efficiently through the adhered drug layer was postulated to interfere with 
carrier dissolution leading to a delay in the release of adhered drug particles. A decrease 
in the dissolution rate with increased mixing times was observed by Nilsson et al. The 
highest dissolution rates of griseofulvin were obtained for griseofulvin-lactose mixtures 
mixed for 750 min; the value being 102 % of kM whereas longer mixing times reduced the 
dissolution rate of griseofulvin to 69 % of kM.
89 
Carrier particle properties 
 Various carrier particle properties, namely solubility, surface texture, and 
mechanical properties, have been studied to understand their effects on dissolution rate 
enhancement from interactive mixtures. Of these properties, carrier solubility was the 
most important factor in determining the degree of dissolution rate enhancement. The 
immediate dissolution of highly soluble carriers delivered the drug in the form of 
dispersed particles, with increased effective surface area and decreased diffusion layer 
thickness. This was observed in a study by Westerberg et al. where griseofulvin was dry 
mixed with sodium chloride carrier. The authors observed that interactive mixtures 
showed rapid dissolution, independent of stirring speed and surfactant concentration, 
whereas the dissolution of pure drug agglomerates increased with increase in 
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theseparameters.87 This indicated that following rapid carrier particle dissolution, the drug 
was delivered as well-dispersed particles. The calculated effective surface area, based on 
the dissolution rate, was similar to the value for the external surface area of primary 
particles measured by permeametry. Interactive mixtures prepared with insoluble carriers 
possessing hydrophilic surface properties, such as Emcompress® and glass beads, had 
lower drug dissolution than that in those with soluble carriers. The low dissolution rate of 
mixtures containing hydrophilic carriers was attributed to the inability of the carrier to 
dissolve and release the drug as dispersed particles in the medium. The drug particles 
remained partly adhered to the carrier, resulting in a lower surface area available for 
dissolution relative to mixtures prepared with soluble carriers.87  
 To study the effects of carrier surface texture on drug dissolution from interactive 
mixtures, carrier materials with different surface properties were formed into interactive 
mixtures with griseofulvin. Similar results for glass beads (smooth texture) and 
Emcompress® (rough texture) indicated that surface texture was not a significant factor 
affecting dissolution.87 
 Commonly, interactive mixtures are formulated into tablet dosage forms, making 
it important to understand the effects of compaction on drug dissolution. Nilsson et al. 
observed that tablets made from interactive mixtures containing lactose and mannitol as 
carriers showed a higher dissolution rate than uncompacted interactive mixtures. The 
increased dissolution rate, after compaction, was attributed to fracture of carrier particles 
upon application of pressure. Consequent breakage of the carrier caused the uncoated 
carrier surface to be exposed to the solvent, resulting in faster carrier dissolution and drug 
release from its surface.89 In another study, Westerberg et al. studied the effects of 
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mechanical properties of carrier on drug dissolution from compacted interactive mixtures. 
Micronized oxazepam was formed into interactive mixtures with mannitol (brittle 
material) and sodium chloride (plastic material) as carriers. Tablets prepared with both 
carriers had dissolution rates comparable to that of uncompacted mixtures. However, 
internal lubrication with hydrophobic magnesium stearate caused a significant reduction 
in the dissolution rate of oxazepam from compacted mixtures made using sodium 
chloride carrier. This was due to the low degree of fragmentation of sodium chloride 
during compaction thereby providing limited, new, and clean surfaces that were not 
coated with the lubricant and resulted in a decreased dissolution rate.90 
 Ibrahim et al. studied the effects of carrier particle size on the dissolution rate of 
griseofulvin from interactive mixtures. The authors observed an 87 % drug release from 
the mixtures made with carriers sized 710–850 µm compared to a 66 % drug release from 
mixtures with carriers sized 1000–2000 µm. This was possibly because a reduction in 
carrier particle size led to an increased number of carrier particles (and carrier surfaces) 
available for interaction with the drug. In addition, the possibility of the drug being 
deposited as multiple layers on the carrier surface was minimized facilitating interaction 
of the carrier with the solvent.91 However, a considerable difference in the size of the 
drug and carrier particles is imperative for forming interactive mixtures, because the 
coarse carrier particles (together with the mixer type) help to break drug agglomerates. 
Therefore, caution must be exercised when selecting the carrier particle size, because low 
size ranges are prone to agglomeration and can therefore provide limited effectiveness.  
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Influence of excipients 
 Surfactants are known to reduce the interfacial tension between drug particles and 
solvents, thereby improving the wettability and solubility of hydrophobic drugs. 
Therefore, several studies have incorporated surfactants into binary drug-carrier 
interactive mixtures to aid agglomerate break down and increase dissolution rate. 
Westerberg et al. observed that the increased dissolution rate on surfactant addition in 
oxazepam-mannitol mixtures was only significant when the degree of surface coverage 
was high. Mixtures with high surface coverage (Rs > 1) are likely to contain a greater 
fraction of agglomerated particles than those with a low Rs value. As surfactants promote 
wetting of hydrophobic drugs and produce an increase in effective surface area by 
breaking down agglomerates, they are expected to be more effective when the degree of 
surface coverage is high. To understand the influence of surfactants on drug dissolution 
from interactive mixtures, the dissolution data of ternary benzodiazepine-lactose-sodium 
lauryl sulphate (SLS) mixtures were modeled using a multiexponential equation. The 
multiexponential equation assumed drug dissolution to occur from distributions of 
dispersed and aggregated particles. Addition of 5 % SLS caused a decreased aggregate 
percentage and an increased dissolution rate constant for aggregated particles compared 
with binary benzodiazepine-lactose mixtures. Particle size analysis of the mixtures by 
laser diffraction provided evidence for a shift to lower aggregate sizes on surfactant 
addition. Furthermore, the increased dissolution rate of binary interactive mixtures, 
following surfactant addition directly to the solvent, was modest compared to when it was 
incorporated in the powder mixture. Therefore, it was concluded that it was necessary for 
the surfactant to be associated with agglomerated drug particles on the carrier surface. It 
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was hypothesized that the surfactant in the mixed drug-surfactant aggregates dissolved 
and provided a high local concentration of surfactant in the aggregate microenvironment 
causing the remaining drug agglomerates to diperse.92 
 The dissolution rate of drugs from interactive mixtures with a high degree of 
surface coverage also increased on adding a disintegrant to the carrier. If the carrier 
material disintegrates readily, the carrier surface area exposed to the dissolution medium 
increases. An increase in the exposure of uncoated carrier surfaces to the solvent results 
in faster carrier dissolution and release of the adhered drug particles from the carrier 
surface. In one study, mannitol and cross-linked sodium carboxymethylcellulose granules 
were used as carrier particles for oxazepam. The dissolution rate of oxazepam from 
mixtures containing disintegrant, sodium carboxymethylcellulose in the carrier was 
higher than that of mixtures containing mannitol particles as the carrier.87 Similar results 
were reported when nifedipine was coated on the surface of superdisintegrants such as 
sodium starch glycolate and croscarmellose sodium.92 
 Addition of micronized inorganic excipients and fine lactose to binary drug-
carrier interactive mixtures has also resulted in dissolution rate enhancement. The 
superior performance of mixtures containing micronized excipients relative to binary 
drug-carrier mixtures was attributed to the formation of drug-excipient agglomerates on 
the carrier surface. It was speculated that the mixed drug-micronized excipient 
agglomerates would have a greater propensity to deagglomerate than pure drug 
agglomerates, possibly because of a reduced agglomerate strength and a more porous 
packing arrangement. The dissolution rate enhancement of indomethacin was observed 
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by Tay et al. on adding micronized aluminum hydroxide to binary indomethacin-lactose 
interactive mixtures.93, 94 
1.4.5 Dissolution Models 
 Interactive mixtures contain micronized drug particles distributed as dispersed 
particles or small agglomerates on the carrier surfaces. To model drug dissolution from 
interactive mixtures, treating dissolution as if it occurs from two distinct particle 
populations having different mean particle sizes is suitable. Traditional particulate 
dissolution models such as the Hixson-Crowell cube root law is ideally valid for uniform 
spherical particles, in other words, the solid is in the form of a single unit or all units have 
identical properties regarding size, shape, surface, and volume. However, in some cases 
studies have shown polydispersed powders to experimentally follow the cube root law. 
The Hixson-Crowell cube root equation is also derived assuming that all particles have 
the same shape.95 However, this would not be a reasonable assumption for agglomerated 
particle distribution because it is more likely that agglomerates would deviate from 
spherical geometry. Therefore, most studies describing drug dissolution from interactive 
mixtures, treat dissolution as a two-stage process involving the rapid dissolution of 
dispersed particles consequent with the slow dissolution of agglomerated particles 
without making any assumptions of particle size or shape, as described below. 
Multiexponential dissolution models 
 Alway et al. mathematically modeled diazepam dissolution from lactose 
interactive mixtures. In accordance with previous studies, diazepam dissolution occurred 
rapidly at low drug concentrations. To represent the dissolution profiles by rate constants, 
conventional models were used to fit the dissolution data. The Hixson-Crowell model did 
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not linearize the data, because the model was derived for uniform spherical particles and 
isotropic dissolution, in other words, particle shape was unaltered during dissolution. 
Wagner’s percent undissolved versus time model also provided a poor fit, because 
theoretically it is valid only when the surface area decreases exponentially with time and 
is not applicable for materials with bimodal particle distributions. Based on these 
observations, the authors hypothesized that dissolution from interactive mixtures was a 
two-stage process involving dissolution from dispersed particles and agglomerates of the 
drug, and a biexponential model derived from Wagner’s model was proposed to fit the 
dissolution data.96 The derivation of the biexponential equation from Wagner’s 
dissolution model is given below. This model is valid when there are sink conditions and 
the surface area varies with time. Assuming that the surface area available for dissolution 
decreases exponentially with time, the following equation is obtained: 
)exp(0 tkSS s            (1.37) 
where S is the surface area available for dissolution at time t , 0S  is the surface area 
available for dissolution at 0t , and sk  is the rate constant for surface area decrease. 
Substituting Equation 1.37 in the Noyes-Whitney equation (Equation 1.8, Section 
1.2.2) yields: 
)exp(0 tkSkC
dt
dW
ss            (1.38) 
Integrating Equation 1.38 from time = 0 to time = t  gives: 
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k
SkC
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s
s
t        (1.39) 
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where tW  is the amount of drug dissolved at time t  and 0W  is the amount of drug 
dissolved at 0t . Because 00 W , Equation 1.39 can be written as: 
)]exp(1[0 tk
k
SkC
W s
s
s
t            (1.40) 
At time t ,  
s
s
k
SkC
W 0             (1.41) 
Subtracting Equation 1.40 from Equation 1.41 gives the following: 
)exp(0 tk
k
SkC
WW s
s
s
t            (1.42) 
Taking the logarithm of both sides of Equation 1.42 gives the Wagner model for 
dissolution as follows: 
303.2
log)log( 0
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t           (1.43) 
where )( tWW  is the amount not dissolved at time t . W (Equation 1.41) represents 
the drug amount dissolved at infinite time or the initial drug amount in the formulation.  
  Wagner’s model can be applied to describe drug dissolution from two particle 
populations of different sizes assuming exponential surface area decreases on dissolution. 
Because drug dissolution from interactive mixtures is hypothesized to occur from 
agglomerated and dispersed particles, Equation 1.40 can be written as: 
))exp(1())exp(1( tkWtkWW ddaat         (1.44) 
where aW and dW are the initial weights of the agglomerated and dispersed particles, 
respectively, and ak and dk are the dissolution rate constants describing the surface area 
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changes of the agglomerated and dispersed particles, respectively. Because the term 
totalda WWW  )(  represents the total amount of drug in the mixtures, Equation 1.44 can 
be written as: 
)exp()exp( tkWtkWWW ddaattotal          (1.45) 
where )( ttotal WW  is the amount of undissolved drug at time t . 
 Therefore, a plot of amount undissolved versus time gives a biexponential plot. 
The parameters representing the dissolution of agglomerated particles, namely aW and ak
can be determined from the terminal phase of this plot. The parameters describing the 
dissolution of dispersed particles, namely dW  and dk , can then be determined by 
applying the method of residuals to the amount undissolved versus time data. 
 Alway et al. used Equation 1.45 to model drug dissolution from diazepam-
lactose interactive mixtures with different degrees of drug loading. Nonlinear least 
squares curve fitting was applied to the amount of drug undissolved versus time data. 
Modeling results showed that dk  remained relatively constant across the different drug 
loadings in the mixtures. Conversely, the value of ak decreased with an increase in drug 
loading. In addition, increasing diazepam concentration in the mixtures also increased Wa   
because of low degree of deagglomeration. The overall dissolution rate was a function of 
the rate constants and of Wa and Wd. To support use of the biexponential model, 
environmental scanning electron microscopy (SEM) was used to observe the drug 
dissolution from interactive mixtures with small amounts of water condensed on the 
carrier surface. Microscopy revealed that the carrier dissolved rapidly, releasing the drug 
as agglomerates and dispersed particles. Furthermore, SEM images of the interactive 
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mixtures before dissolution qualitatively showed greater evidence of agglomeration at 
high drug loadings.96, 97 Increased drug agglomeration with an increase in drug loading is 
caused by an incomplete agglomerate break down when mixing. 
 The biexponential model was also applied to study the influence of micronized 
surfactants (SLS and cetrimide) on benzodiazepine dissolution from lactose interactive 
mixtures. SEM showed the presence of mixed drug-surfactant agglomerates on the 
lactose carrier surface. An increase in the surfactant concentration in mixtures caused a 
decrease in aW and an increase in the rate constants, ak and dk . The increase in rate 
constants on surfactant addition was attributed to two factors: an increase in the intrinsic 
dissolution rate of the drug caused by dissolved surfactant in the agglomerate 
microenvironment and a decrease in the mean particle size of agglomerates caused by 
their increased dispersion.91 
Particle size analysis 
 Kinetic particle sizing approaches, such as laser diffraction analysis, have been 
used to determine the percentage and size distributions of agglomerated and dispersed 
drug particles after adding interactive mixtures to the dissolution media.91, 98, 99 To 
measure particle size using laser diffraction size analysis, a laser passes through a sample 
dispersed in suitable liquid media and is diffracted by the particles. In general, light 
scatters at smaller angles off large particles than small particles. The intensity and angle 
of light scattered by the particles is detected and then converted by the analyzer into a 
particle size distribution. Using laser diffraction analysis, particle sizes between 0.2 µm 
to 2000 µm can be measured.100  
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 Zhao et al. used laser diffraction analysis to determine the effects of surfactants 
on the degree of agglomeration of diazepam in lactose interactive mixtures. The degree of 
agglomeration was obtained by dividing the area under the agglomerate distribution by 
the total volume concentration of the particles. Binary diazepam-lactose interactive 
mixtures added to distilled water showed a bimodal distribution with modes of 
approximately 50 µm and 7 µm representing agglomerated and dispersed drug particles, 
respectively. The same type of bimodal distribution was observed when ternary mixtures 
of diazepam-SLS-lactose were added to distilled water. However, the modes appeared at 
34 µm and 4.8 µm in the presence of a surfactant, which enhanced agglomerate 
dispersion.99 
 Laser diffraction analysis has also been used to understand the effects of drug 
loading on the deagglomeration profile.98 The following equation was used to fit the 
deagglomeration profiles: 
)exp(00 tkCCC aaa            (1.46)  
Where Ca is the percentage mass of agglomerates present in the medium at time t, C0 is 
the initial mass percent of nondispersible agglomerates, and C0a is the initial mass percent 
of agglomerates that undergo deagglomeration with the rate constant ka. Increased 
benzodiazepine concentration in the mixture increased the values of C0, whereas adding 
SLS to the mixture decreased this value. Based on this study, the authors concluded that 
deagglomeration profiles can serve as useful tools during formulation as the knowledge 
of parameters, such as C0 and ka, may help to adopt specific strategies for formulation 
optimization.  
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 In conclusion, the biexponential model (Equation 1.45) representing the 
dissolution of dispersed and agglomerated particles has been used to describe drug 
dissolution from interactive mixtures. This model enables determination of the initial 
percentages of agglomerated and dispersed particles in mixtures and the rate constants 
describing dissolution. The information on the effective surface area of agglomerated and 
dispersed particles, the percent total surface area of drug particles available for 
dissolution and the parameters related to particle size of the agglomerated and dispersed 
particles can be further determined from the biexponential model and is explained in 
detail in Chapter 4 (Section 4.2.6). 
1.5 Cefuroxime Axetil: Drug Profile 
1.5.1 Cefuroxime Axetil (CFA) Diastereomers 
 Cefuroxime axetil (CFA) is an orally available ester prodrug of cefuroxime 
(Figure 1.9), a second-generation injectable cephalosporin antibiotic. CFA is synthesized 
by esterification of the carboxylic acid group of cefuroxime to produce the  
1’-acetoxyethyl ester derivative (Figure 1.10), making the drug orally bioavailable. Upon 
oral administration, CFA is absorbed from the gastrointestinal tract and hydrolyzed by 
esterase enzymes in the intestinal mucosa and plasma releasing the parent drug, 
cefuroxime, which has bactericidal effects against several gram-positive and gram-
negative microorganisms. CFA is commonly used in the treatment of a respiratory and 
urinary tract infections.101 Esterification of cefuroxime to produce CFA is carried out 
using racemic (R,S)-acetoxyethyl bromide, which produces an asymmetric center at 
position 1’ of the ester group. Although CFA contains three chiral carbon atoms at 
positions 1’, 6, and 7 (indicated in Figure 1.10), the configuration differs only at position 
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1’ indicating that the molecule exists as a pair of diastereomers. The diastereomers are 
isomer A (1’S, 6R, 7R) and isomer B (1’R, 6R, 7R) as shown in Figure 1.10. Biological 
studies in dogs and rats have indicated that these isomers were hydrolyzed at different 
rates by esterase enzymes in the intestine and plasma. In all cases, isomer A was 
hydrolyzed to nonabsorbable cefuroxime faster than isomer B.102 
 
 
 
Figure 1.9. Chemical structure of cefuroxime (parent drug). 
 
 
 
Figure 1.10. Chemical structure of cefuroxime axetil diastereomers. 
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Because the diastereomers of CFA differ in configuration at only one chiral 
carbon atom, different distances between nonbonded atoms causes changes in the overall 
molecular shape and geometry. The differences in the packing of individual 
diastereomers in the crystal lattice causes crystalline diastereomers to exhibit distinct 
physical properties such as solubility and melting point. Previous studies have reported 
the melting points of crystalline isomer A and B to be 194–196 °C and 132–134 °C, 
respectively.103 In another study, two crystalline forms of the isomers A and B of CFA 
were observed. These were referred to as forms AI and AII for isomer A with melting 
points of  201.9 °C and 191 °C, respectively, and form BI and BII with melting points of 
133.4 °C and 124.3 °C for isomer B, respectively. Form BII was found to be a 
hemihydrate form, whereas all others were nonsolvated. Powder X-ray diffractometry 
patterns for the different crystalline forms were distinct which permitted their 
identification.104 
Various crystalline solid structures can be formed between diastereomers upon 
crystallization from a melt or a solution as described in Chapter 1 (Section 1.1.2). The 
type of structure influences properties such as solubility and stability. In this project, 
thermal analysis was to construct a phase diagram to gain insight into the solid-state 
structure formed by CFA diastereomers. Further, phase solubility studies and intrinsic 
dissolution rate determination on diastereomer mixtures of different compositions were 
performed. These studies were conducted to understand the solution behavior of CFA 
diastereomers. 
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1.5.2 Cefuroxime Axetil (CFA) Dissolution Rate-Limitation 
The formation of CFA, by esterification of the carboxylic acid group of 
cefuroxime, is intended to improve the lipophilicity and membrane permeability of the 
parent drug. Despite this, oral products of CFA exhibit a low bioavailability of 21–44 % 
(after fasting) and 34–55 % (after food).105  The increased bioavailability, when 
administered with food, is due to a long residence time in the upper gastrointestinal tract 
during which the drug can dissolve, indicating that CFA exhibits a dissolution rate-
limited bioavailability. CFA is classified as a Biopharmaceutics Classification System 
(BCS) Class II drug (poor aqueous solubility, good membrane permeability). Because 
dissolution rate-limited bioavailability caused by poor aqueous solubility can be partly 
overcome by the use of high-energy solid forms, CFA is present as the amorphous solid 
form in commercially available preparations.105 
Formulation approaches, such as particle size reduction to increase surface area 
have been used to improve the dissolution rate (according to Noyes-Whitney equation, 
Equation 1.8). In one study by Dhumal et al. CFA particles of different sizes were 
prepared and their dissolution and in vivo plasma concentration-time profile in rats were 
compared (Figure 1.11). The smaller particles showed a faster dissolution rate and a 
significantly high in vivo bioavailability (as represented by the area under the plasma 
concentration-time curve).106 
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Figure 1.11. Dissolution profile and Plasma concentration-time profile following the 
administration of unprocessed CFA 20–50 μm (●); spray-dried CFA 10–100 μm (■); PPT-CFA 
(precipitated CFA, 1–10 μm) (○); and SONO-CFA (sonoprecipitated CFA,  130 nm) (▲) in rats. 
Reproduced from Dhumal et al. with permission from Elsevier.106 
  
Although particle size reduction resulting in SSA increase is a commonly used 
approach to enhance dissolution rate, reduced rates have been reported in some cases. For 
example, one study compared the dissolution of crystalline particles with SSA of 
6.24±0.03 m2/g to amorphous nanoparticles of CFA with SSA of 16.91±0.05 m2/g. 
Although the initial dissolution rates (under sink conditions) for the nanoparticles were 
higher (attributable to increased solubility), the dissolution rates rapidly became 
indistinguishable.65 Based on high SSA and solubility, the Noyes-Whitney equation 
predicted an improved dissolution profile for the nanoparticles. The anomalous result was 
attributed to the propensity of nanoparticles to agglomerate causing a decrease in the 
effective surface area. Agglomeration caused the dissolution rate to be lower than that 
expected based on the solid’s total SSA. To take advantage of the surface area increase 
afforded by particle size reduction, agglomerated drug particles must to be broken down 
into dispersed drug particles or small clusters. This can be achieved by mixing 
agglomerated drug particles with coarse carrier particles to form interactive mixtures 
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(described in detail in Section 1.4). In this project, the interactive mixing approach was 
applied to improve the dissolution rate of the model drug, CFA, which suffers from 
dissolution rate-limited oral bioavailability 
1.6 Research Objectives 
 The overall goal of this project was to understand how interactive mixing affects 
the dissolution rate of the antibiotic drug, CFA. This goal required a deeper 
understanding of the solid-state and the solution behavior of CFA diastereomers. The 
information obtained from the diastereomer studies was combined with a formulation 
approach using interactive mixing to investigate the dissolution rate of CFA from 
interactive mixtures with an aqueous-soluble carrier. The following specific outcomes 
were achieved:  
1) A phase diagram describing the solid-state behavior of CFA diastereomers was 
constructed. 
2) The effects of varied diastereomer composition on the overall solubility were 
determined, and an interaction between the diastereomers in solution was identified.  
3) The mechanism underlying dissolution rate enhancement in interactive mixtures, as 
compared to drug agglomerates and physical mixtures was determined using a model 
relevant to heterogeneous particle distributions to analyze dissolution data of interactive 
mixtures of amorphous CFA and milled particles of crystalline drug. 
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Chapter 2: Solid-Liquid Phase Diagram of Diastereomers of Cefuroxime 
Axetil 
 
2.1 Introduction 
This chapter focused on identification of the solid-state structure formed between 
cefuroxime axetil (CFA) diastereomers.  Diastereomers can crystallize from an equimolar 
mixture as either homochiral crystals (conglomerate) or heterochiral crystals. The 
crystalline forms differ in physical properties such as solubility and melting point. In 
most cases, diastereomers form conglomerates The phase diagram of  conglomerates 
exhibits eutectic behavior. A physical mixture of eutectic composition may have different 
properties than that of a fused mass of the components affecting solubility and stability of 
the dosage form. As CFA is present in commercial preparations as a diastereomer 
mixture (isomer A and isomer B, Figure 1.10, Chapter 1: Section 1.5.1), it is of value to 
determine the eutectic composition and melting point. In this chapter, thermal analysis 
utilizing differential scanning calorimetry (DSC) was used to construct a phase diagram 
in order to determine the eutectic composition and melting point. 
2.2 Materials and Methods 
2.2.1 Materials 
Commercially available amorphous CFA (Dhanuka Laboratories, Mumbai, India) 
was used as the starting material. Methanol (Alfa Aesar, Ward Hill, MA, HPLC grade) 
was used for separation and crystallization of the diastereomers. All proton NMR (1H-
NMR) spectra were recorded in dimethylsulfoxide-d6 (99.9 atom % D) (Sigma-Aldrich, 
St. Louis, MO). 
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2.2.2 Separation and Crystallization of Diastereomers 
The diastereomers were separated from the commercially available amorphous 
CFA (equimolar mixture of diastereomers). Methanol was used to selectively crystallize 
the two diastereomers because they have very different solubilities in methanol. 
Approximately 5 g of amorphous CFA was added to 100 ml of methanol, heated to 60 °C 
and held at this temperature for 30 min with constant stirring. The slurry obtained was 
filtered, and as the filtrate was allowed to cool to room temperature the initial batch of 
crystals obtained were collected, dried and subjected to 1H-NMR spectroscopy analysis to 
determine their identity and diastereomeric purity. The first batch of crystals was named 
Lot1 crystals. The mother liquor remaining was then completely evaporated and the 
deposited crystals were also dried and subjected to 1H-NMR spectroscopy (Lot 2 
crystals). Proton NMR spectra (1H NMR) of the crystalline materials obtained from 
methanol were recorded on a Bruker WH-400 (400 MHz) spectrometer in 
dimethylsulfoxide-d6. The chemical shift values are expressed in parts per million (ppm) 
relative to tetramethylsilane as an internal standard. The diastereomers were 
distinguished using the chemical shift of the proton at the 1’ position of the molecule 
(indicated in Chapter 1: Figure 1.10). The reported chemical shift values are 6.89 ppm 
(for isomer A) and 7.01 ppm (for isomer B) and the peaks appear as a quartet. The 
relative diastereomeric purities of the samples were determined by integrating the areas 
under the peaks. 
2.2.3 Solid State Characterization of the Diastereomers of Cefuroxime Axetil 
In addition to diastereomeric purity, the solid phase of each batch of crystals was 
characterized using thermal analysis and powder X-ray diffraction. Melting points and 
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diffraction patterns were compared to those previously reported in order to ascertain the 
polymorphic forms of the diastereomers. 
 Differential scanning calorimetry (DSC) analyses were performed on a Model 
Q100 DSC (TA Instruments, New Castle, DE) under a constant nitrogen purge  
(50 ml/min). A three-point temperature and enthalpy calibration was performed using  
o-terphenyl, indium and tin standards. The cell constant calibration was performed using 
indium. Samples (3.5–4.5 mg) were hermetically sealed in aluminum pans and heated at 
10 °C/min up to 210 °C. Experimental melting point values were determined as the onset 
melting temperature and compared with reported values in literature that were determined 
under similar conditions of heating rate.  
PXRD patterns were recorded at room temperature on an X’Pert Pro MPD system 
(P’Analytical B.V., Almelo, the Netherlands) equipped with a copper anode  
(λ=1.54016 Å) and an X’Celerator™ detector. The operational voltage and amperage 
were set to 45 kV and 40 mA, respectively. Samples were thoroughly ground and 
mounted on a back-filled, aluminum sample holder and were analyzed in continuous 
mode with a step size of 0.0170 °2θ and a step time of 31.75 s over the range of 2–60 °2θ. 
The samples were spun at 16 rpm during the measurements. Diffractograms were plotted 
as diffraction intensity vs. scattering angle (° 2θ) using X’Pert HighScore Plus software. 
2.2.4 Construction of the Phase Diagram (T-χ diagram) for Diastereomers of 
Cefuroxime Axetil 
Diastereomer mixtures were prepared for DSC analysis by accurately weighing 
appropriate quantities of the crystalline diastereomers to produce various mixtures in  
10 % increments. The mixtures were then thoroughly ground, by hand in a mortar to 
promote intimate contact between the different crystals. Samples (3.5–4.5 mg) were 
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hermetically sealed in aluminum DSC pans. The various melting peaks of CFA overlap 
with each other obscuring the individual onset temperatures. Therefore, the peak 
temperature of each endotherm was used. As peak temperature is sensitive to variations 
in heating rate, individual samples of each composition were heated at 1, 2 and 3 °C/min 
up to 210 °C (n=2 replicates or more at each rate). The peak temperatures of the melting 
endotherms were then plotted against the heating rate, and linear regression was used to 
obtain the peak temperature at zero heating rate (Tpeak, 0). The phase diagram was 
constructed by plotting the Tpeak, 0 values obtained from the thermograms for each 
composition against the % of isomer B in the mixture. 
2.3 Results and Discussion 
2.3.1 Spectroscopic, Thermal and Diffraction Analyses of Crystalline Diastereomers 
The 1H-NMR spectra for commercially available amorphous CFA, the first batch 
of crystals obtained from methanol (named as Lot 1 crystals) and the crystalline material 
deposited from the mother liquor (named as Lot 2 crystals) are shown in Figures 2.1a, 
2.1b and 2.1c, respectively. The chemical shift values (in ppm) of the proton on the  
1’ carbon, which appear as quartet peaks, were used to distinguish between the 
diastereomers. This peak was specifically used for distinction, as the diastereomers differ 
in configuration at only this asymmetric carbon atom.107 In Figure 2.1a both sets of 
quartet peaks were present and the ratio of their integrated areas was found to be 1:1 
indicating that commercial amorphous CFA is an equimolar mixture of diastereomers. 
Lot 1 crystals obtained from the methanol filtrate showed only one set of quartet peaks at 
a chemical shift of 6.89 ppm indicating the presence of only isomer A (Figure 2.1b). 
Therefore isomer A could be isolated with a purity approaching 100 %. Although both 
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sets of quartet peaks were present in the 1H-NMR spectrum of Lot  2 crystals  (Figure 
2.1c), the ratio of the two, quartet peak areas at chemical shift values of 7.01 ppm and 
6.89 ppm were 1:0.18, indicating that this batch of crystals contained 85 % of isomer B 
and 15 % of isomer A. Further efforts to isolate isomer B did not significantly improve 
the diastereomeric purity. This was attributed to the slight solubility of isomer A in 
methanol such that it could not be completely removed from the methanol filtrate. In 
order to determine the sensitivity of the NMR method, 2 % w/w increments of isomer B 
were added to Lot 1 crystals (form AI). The area under the peaks appearing at chemical 
shift values of 6.89 ppm and 7.01 ppm were integrated.  There was a proportional 
increase in area under the peak at 7.01 ppm (corresponding to isomer B) as the amount of 
isomer B in the mixtures increased. This enabled quantification of small percentages of 
isomer B (< 2 % w/w) in a matrix of isomer A. 
Thermal analysis and PXRD were used to confirm the diastereomeric identity as 
well as the solid form of each material obtained upon crystallization from methanol. The 
DSC thermogram of Lot 1 crystals obtained from methanol (1H-NMR spectra shown in 
Figure 2.1b) is shown in Figure 2.2a. A single endotherm with an onset temperature of 
202.9 °C was seen. This value was compared with the melting temperatures for the 
reported solid forms of each diastereomer of CFA, and it was found to correspond with 
that for form AI of isomer A (reported melting temperature is 201.9 °C). The PXRD 
pattern for these crystals (Figure 2.2b) showed characteristic peaks for form AI.104 Based 
on this data, the crystals from Lot 1 were confirmed as form AI. It is expected that the 
first batch of crystalline material deposited from methanol to be isomer A based on its 
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lower solubility in methanol compared to isomer B, creating a higher level of 
supersaturation and consequently a greater driving force for crystallization. 
 
 
Figure 2.1.1H-NMR spectra (in d6-dmso) (a) Commercially available CFA (b) First batch of 
crystals from methanol (Lot 1 crystals) (c) Crystalline material deposited from mother liquor (Lot 
2 crystals). Peaks shown correspond to the proton highlighted in bold of the CH3-CH group. 
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Figure 2.2. (a) DSC thermogram of first batch of crystals from methanol (Lot 1 crystals) obtained 
at heating rate of 10 °C/min (b) Powder diffractogram of first batch of crystals from methanol 
(Lot 1 crystals). The reported pattern is that of form AI.104 
 
The PXRD pattern of Lot 2 crystals is shown in Figure 2.3. As the 1H-NMR 
spectra of this material (Figure 2.1c) showed the presence of both sets of quartet peaks it 
was concluded that this material was a mixture of diastereomers.  The powder diffraction 
pattern of the crystalline material showed characteristic crystalline peaks for both form BI 
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and form AI (Figure 2.3). The peak positions of the individual crystalline diastereomers 
were preserved in the crystalline mixture, suggesting the absence of crystal modification 
or formation of a racemate. This indicates that the diastereomers crystallized separately to 
form a mixture of homochiral crystals. Purification of Lot 2 crystals in order to improve 
the content of isomer B was attempted using solvents such as ethyl acetate, acetone and 
hexane. Despite this the maximum purity of isomer B that could be achieved was 85 % in 
a diastereomer mixture. 
 
 
Figure 2.3. PXRD patterns (a) Mixture containing isomer A and isomer B (0.18:1 ratio) (b) 
Reported pattern of form AI (c) Reported pattern of form BI.104 
  
 
65 
 
2.3.2 Differential Scanning Calorimetry (DSC) Thermograms of Diastereomer 
Mixtures 
Representative DSC thermograms of mixtures containing 0 % to 85 % isomer B 
at three different heating rates are shown in the Appendix Section. 
Selected DSC thermograms of mixtures with containing 0 % to 85 % isomer are 
shown in Figure 2.4. All thermograms shown were obtained at a heating rate of 2 °C/min 
to illustrate the overall characteristics of the thermal behavior. Based on Figure 2.4, 
isomer A showed a single, sharp melting peak in the absence of isomer B (0 % isomer B) 
with Tpeak, 0=183 °C. As the concentration of isomer B in the mixtures increased, a second 
endothermic peak appeared with Tpeak, 0 of approximately 125 °C and this peak 
overlapped with the melting peak of isomer A. Melting peaks of the diastereomer 
mixtures were broader than that observed in the pure isomer A sample. The peak 
temperature of the lower melting peak remained consistent even as the ratio of the 
isomers in the mixtures was varied. In addition, the peak temperature and size of the 
original isomer A melting endotherm both decreased as the amount of isomer B present 
increased up to a concentration of 70 % isomer B. The depression in the peak melting 
temperature of isomer A with an increase in concentration of isomer B in the mixture 
indicated that the isomers were miscible. A single endotherm was observed in the mixture 
containing 75 % isomer B with a Tpeak,0 of 125.1 °C. Further increasing the isomer B 
concentration above 75 % caused the second endotherm to reappear. Since the peak 
temperature of the lower melting endotherm remained consistent even as the 
concentration of the isomers was varied, the peak was attributed with melting of the 
isomer A/isomer B eutectic mixture. Formation of a eutectic mixture can be explained by 
localized melting between the diastereomers upon application of mechanical stress and 
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their miscibility in the liquid state (caused by chemical similarity between the molecules). 
As the diastereomers melt together, the net entropy change is greater than if they were to 
melt separately. This causes the mixture to exhibit a melting point that is lower than 
either pure component, assuming that the heat of fusion is relatively constant and is a 
weighted sum of the individual constituents.9 
The dependence of melting temperature on heating rate was clearly observed for 
all diastereomer mixture compositions (Appendix Section). For the same mixture 
composition at different heating rates, the peak shape looked similar, but the peak 
position was different. As the heating rate increased, the peak shifted to a higher 
temperature due to thermal lag which is inherent in a DSC measurement.  
The possibility of polymorphic transformation upon grinding of crystalline 
diastereomers to obtain the various mixtures was ruled out using PXRD analysis. The 
PXRD pattern of the ground mixture containing 85 % isomer B is shown in Figure 2.3. 
The peak positions of form AI and form BI were retained suggesting the absence of any 
crystalline modification upon grinding. 
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Figure 2.4. DSC thermograms of diastereomer mixtures of CFA with various compositions. All 
thermograms were obtained at a heating rate of 2 °C/min. 
 
2.3.3 Phase Diagram (T-χ) of Diastereomers 
The phase diagram of the diastereomer mixtures of CFA was constructed by 
plotting the peak temperatures extrapolated to zero heating rate (Tpeak, 0) values against 
the % isomer B. At all mixture compositions, except for 75 % isomer B, there were two 
endotherms, corresponding to eutectic mixture melting and liquidus temperature. The 
composition of the eutectic mixture was 75 % isomer B and the eutectic melting 
temperature was 124.8±0.5 °C. Below the eutectic composition (χe) or 75 % isomer B, 
the higher melting endotherm corresponds to the depressed melting of excess isomer A in 
the mixture. The higher melting endotherm in compositions above χe represents the 
depressed melting of isomer B. At 75 % isomer B composition, the single melting 
endotherm represents the eutectic composition. 
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Table 2.1 summarizes the peak melting temperatures obtained at the different 
heating rates as well as the peak temperature extrapolated to zero heating rate (Tpeak,0) for 
mixtures ranging in concentration from 0 % to 85 %  isomer B. 
 
 
Figure 2.5. Phase diagram of diastereomers of CFA. The y-axis represents the peak melting 
temperature extrapolated to zero heating rate (Tpeak,0) and the error bars represent the standard 
error of the intercept obtained by linear regression of the peak melting temperature versus heating 
rate (n=2 replicates at each heating rate). 
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Table 2.1. Thermal data for disatereomer mixtures containing 0 % to 85 % isomer B. 
 
 
*Values represent Average (±SD) of at least n=2 replicates at each heating rate. 
**Values represent the y-intercept (±SE) of the plot of peak melting temperature vs. 
heating rate 
% 
isomer 
B 
 
 
Heating 
rate 
(°C/min) 
 
Eutectic peak 
temperature(°C)* 
 
Liquidus peak 
temperature 
(°C)* 
Eutectic peak 
temperature 
extrapolated 
to zero heating 
rate (°C)** 
Liquidus peak 
temperature 
extrapolated to 
zero heating 
rate (°C)** 
 
0 
1 - 187.2 (0.9) - 183 (0.8) 
2 - 192.3 (0.2) 
3 - 196.1 (0.3) 
 
10 
1 127.1 (1.5) 184.9 (0.9)  
125.0 (1.3) 
 
181.1 (0.9) 2 128.6 (1.4) 187.4 (0.4) 
3 130.9 (1.3) 192 (0.1) 
 
20 
1 127.9 (0.2) 179.1 (1.2)  
125.3 (0.6) 
 
175.8 (1.4) 2 130.6 (1.3) 181.2(1) 
3 133.2 (0.8) 185.6 (0.9) 
 
30 
1 126.9 (1.3) 176.1(1.1)  
124.6 (1.0) 
 
171.4 (1.5)  129.9 (1.2) 180.6 (1.2) 
3 131.9 (0.3) 185.3 (1.4) 
 
40 
1 126.6 (0.4) 171.2 (0.2)  
123.7 (0.8) 
 
168.6 (0.5) 2 129.4 (1.4) 174.4 (0.8) 
3 131.3 (0.5) 177.3 (0.7) 
 
50 
1 127.6 (0.4) 167.9 (0.7)  
124.8 (0.9) 
 
163.9 (1.4) 2 131.7 (0.6) 174.9 (1.2) 
3 134.9 (1.1) 177.9 (0.9) 
 
60 
1 128.0 (1.3) 164.5 (1.9)  
124.8 (2.1) 
 
159.7 (1.6) 2 129.8 (1.5) 169.5 (0.8) 
3 133.7 (2.1) 174.1 (2.2) 
70 1 127.7 (0.3) 159.3 (1.2)  
124.4 (0.9) 
 
154.6 (1.3) 2 130.3 (1.7) 165.8 (1.7) 
3 134.0 (0.7) 169.6 (1.4) 
 
75 
1 127.3 (0.7) -  
125.1 (0.4) 
 
- 2 129.2 (0.1) - 
3 131.6 (0.1) - 
80 1 127.3 (0.8) 134.1 (0.5)  
125.5 (0.7) 
 
131.5 (0.6) 2 128.8 (1.1) 137.1 (0.8) 
3 130.8 (0.9) 139.3 (0.8) 
85 1 127.2 (0.7) 134.7 (0.2)  
124.5 (0.7) 
 
132.9 (0.5) 2 128.9 (0.4) 136.0 (0.3) 
3 131.9 (0.7) 138.0 (0.9) 
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2.4 Conclusion 
Diastereomers of CFA were separated and crystallized from an equimolar mixture 
using methanol as the solvent. Differential scanning calorimetry (DSC) analysis was used 
to observe the melting behavior of different diastereomer mixture compositions. The 
binary solid-liquid phase diagram of mixture compositions ranging from 0 to 85 % 
isomer B indicated formation of a eutectic mixture with a melting point of 124.8±0.5 °C 
and a composition of 75 % isomer B. PXRD supported the conclusion that the 
diastereomers formed a eutectic mixture, based on preservation of crystalline peaks of 
both components in the mixture. A physical mixture of eutectic composition may have 
different properties than that of a fused mass of the components affecting solubility and 
stability of the dosage form and therefore it is important to determine if the components 
used together in a formulation form a eutectic mixture.  
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Chapter 3: Solubility and Dissolution Studies on Diastereomers of 
Cefuroxime Axetil 
3.1 Introduction 
 Cefuroxime axetil (CFA) is present in commercial preparations as an equimolar 
mixture of diastereomers assigned as isomer A (1’S, 6R, 7R) and isomer B (1’R, 6R, 7R) 
(Figure 1.10, Chapter 1). In the previous chapter (Chapter 2) it was observed that the 
crystalline diastereomers formed a eutectic mixture with a composition of 75 % isomer B 
and a melting temperature of 124.8±0.5 °C. Pharmaceutical operations such as milling 
and tableting causes contact between components of a formulation, and can lead to 
contact induced melting point depression and formation of eutectic mixtures. Although 
CFA is present in commercial products in the amorphous form, traces of crystalline 
diastereomers may remain in solid CFA which may cause formation of eutectic.  Eutectic 
formation can affect the solubility and stability of the final dosage form104, 106  In addition 
to the studying the nature of the solid-state structure of the diastereomers, it is also 
equally important to understand the behavior of the diastereomers in solution, as 
commercial preparations contain both diastereomers. Any interaction, such as formation 
of a soluble or insoluble complex, can impact the solubility of CFA products.   
 This chapter focused on performing phase solubility studies to ascertain solution 
behavior of CFA diastereomers, that is, possible formation of a complex between the 
diastereomers.10 In order to further confirm or rule out the possibility of an interaction 
between the diastereomers in solution, intrinsic dissolution rate (IDR) studies on 
diastereomer mixtures of different compositions was carried out. A diffusion layer model 
developed by Higuchi et al. that describes the dissolution of compressed binary mixtures 
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containing interacting and non-interacting components was applied to the solubility 
data.11, 12  Experimentally obtained IDR values for diastereomer mixtures of three 
different compositions were compared to the theoretical values obtained from the 
Higuchi model. The main purpose of this investigation was to study the behavior of 
diastereomers in solution and calculate the diastereomer ratio that demonstrates the 
highest dissolution rate based on the Higuchi model.11, 12 
3.2 Materials and Methods 
3.2.1 Materials 
 Form AI of isomer A (Lot 1 crystals) obtained by methanol crystallization as 
described in Chapter 2 (Section 2.2.2) and a diastereomer mixture containing 75 % 
isomer B  (present as form BI and  form AI, named as Lot 3 crystals) were used for phase 
solubility and intrinsic dissolution rate studies. Concentrated hydrochloric acid (36 % 
w/w aqueous solution, Lot No. A25X018, Alfa Aesar, Shore Road, Lancashire) and 
deionized water were used to prepare 0.07 N hydrochloric as the medium for solubility 
and dissolution studies. This medium was degassed prior to use. Cefuroxime axetil 
reference standard (1:1 diastereomer ratio) available from the United States 
Pharmacopiea (Category No. 1098220) was used for comparison with the bulk drug and 
development of a calibration curve for quantification. 
3.2.2 Ultraviolet (UV) spectroscopic analysis 
Instrumentation 
UV spectroscopic analysis was used to determine the concentration of dissolved 
cefuroxime axetil. Analysis was performed using a UV-Vis spectrophotometer (HP 
Agilent 8453) equipped with Chemstation software (Rev. A.10.01, Agilent 
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Technologies). Samples were scanned between 190 and 400 nm and quantification of the 
dissolved drug was carried out at the wavelength of maximum absorbance (λmax) which 
was 281 nm.  
Preparation of solutions 
 Standard stock solutions of 1.96×10-4 M of cefuroxime axetil (CFA) (n=3 
replicates) were prepared by dissolving accurately weighed amount of the commercially 
available drug (equimolar diastereomer mixture) in 0.07 N hydrochloric acid. The 
solution was filtered through a 0.22 μm polypropylene membrane filter (VWR 
International, Radnor, Pennsylvania). Calibration standards were then prepared at 
concentrations of ranging from 1.99×10-6 M to 4.80×10-5 M from the stock solution by 
appropriate dilutions with 0.07 N hydrochloric acid. The UV analytical method for 
quantification of CFA was validated as per ICH Q2A guidelines for linearity and range, 
accuracy, precision, limit of detection (LOD) and limit of quantitation (LOQ).108 
Calibration curves were also prepared with Lot 1 crystals (form AI) and Lot 3 crystals 
(75 % isomer B and 25 % isomer A) in 0.07 N hydrochloric acid. This was done to 
ascertain the influence of various compositions of diastereomers on the absorption 
spectrum. A calibration curve was also made in a lower concentration range from 
1.99×10-8 to 4.80×10-7 M in order to ensure that the linear relationship between 
absorbance and concentration was still maintained at lower concentrations. This was 
necessary to quantify lower concentrations of dissolved drug. 
Linearity and Range 
 The linear relationship was evaluated across the range of the analytical procedure. 
The calibration curves were constructed with 13 concentrations ranging from  
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1.99×10-6 M to 4.80×10-5 M (n=3 replicates each). The absorbance of the drug solution 
was considered for plotting the linearity graph. The average value of absorbance at each 
concentration was plotted against the concentration (M). The linearity was evaluated by 
linear regression analysis, which was calculated by linear least square regression method 
using Microsoft Excel®. The correlation coefficient and residual sum of squares was 
used to evaluate linearity. 
Accuracy and Precision  
 Accuracy and precision of the of the assay method were evaluated for both intra-
day and inter-day variations at three different concentrations, 1.18×10-5 M, 2.35×-10-5 M 
and 3.92×10-5 M, representing low, medium and high concentrations, respectively, for 
three days. Accuracy and precision were expressed in terms of percent mean recovery 
and percent relative standard deviation (% RSD). Intra-day precision refers to variations 
in the recovery values obtained upon analyzing the samples within the laboratory over a 
short period of time during the day. Intermediate precision represents intra-assay 
variations measured across three different days. 
Limit of detection and quantitation 
Limit of detection (LOD) and limit of quantitation (LOQ) were calculated from 
the standard deviation of the response (σ) and slope (s) of the calibration curve obtained 
from multiple calibration curves. The response (σ) was measured as the standard 
deviation of the intercepts and the slope (s) was the mean slope of multiple calibration 
curves ranging in concentration from 3.99×10-6 to 3.99×10-5 M.  LOD was calculated as 
3.3σ/S and LOQ as 10σ/S.  
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3.2.3 Solubility Studies of Diastereomers 
 Solubility measurements Lot 1 crystals (form AI) crystals were carried out in 
0.07 N hydrochloric acid medium. Excess Lot 1 crystals were added to medium 
maintained at 37±1 °C in a temperature controlled water-bath shaker. Samples (3 ml) 
were withdrawn, filtered using a 0.22 µm polypropylene filter, diluted with blank 
medium and analyzed for dissolved drug content using a validated ultraviolet 
spectroscopic assay method. The study was continued until the concentration of dissolved 
drug remained constant with time and the plateau concentration was taken to be the 
equilibrium solubility of form AI. This study was performed in triplicate. 
 As crystalline isomer B (form BI, confirmed by PXRD analysis, Figure 2.3, 
Chapter 2) could not be isolated with purity greater than 85 %, solubility determination 
of isomer B crystals involved a phase solubility technique. Phase solubility studies of 
isomer B in the presence of Lot 1 crystals (form AI) were performed at 37±1 °C 
according to the method of Higuchi et al.10 In this method, excess Lot 1 crystals were 
added to 20 ml of pre-equilibrated 0.07 N hydrochloric acid in scintillation vials. A 
known amount of crystalline diastereomer mixture containing 75 % isomer B (Lot 3 
crystals) was added to the vials, and the vials were placed in a temperature-controlled 
water bath shaker. Samples were withdrawn after a suitable equilibration period (usually 
24 h) in order for the system to attain equilibrium. The samples were filtered using a  
0.22 µm polypropylene filter, diluted with blank medium and analyzed for the total 
dissolved isomer concentration (both diastereomers) using a validated UV assay method. 
Additional quantities of Lot 3 crystals were added to the vials and the total isomer 
concentration was measured. In all cases, Lot 1 crystals were added in excess such that 
they were always maintained at their equilibrium solubility. The total isomer 
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concentration (mg/ml) was plotted against the amount of isomer B added (mg). The 
observed value of total isomer concentration was compared with the theoretical 
concentration of the isomers to ascertain the possibility of interaction or formation of a 
complex.10 
3.2.4 Intrinsic Dissolution Rate Studies of Diastereomer Mixtures 
 Intrinsic dissolution rate (IDR) is defined as the dissolution rate of a substance 
under the condition of constant surface area. IDR is dependent on solid state properties, 
and extrinsic factors such as hydrodynamic conditions, pH, temperature and fluid 
viscosity and is independent of particle size and shape frequently encountered in 
traditional dissolution experiments. In order to measure IDR, a compact of constant 
surface area of the material under study is prepared by compression and exposed to the 
dissolution medium while maintaining a constant temperature, pH and stirring rate.109  
Noyes-Whitney equation (Equation 1.8, Chapter 1) under sink conditions can be 
rearranged to give an expression for IDR (Equation 3.1) as follows: 
h
DC
S
dtdW s
/
            (3.1) 
where the term 
S
dtdW /
is the IDR. In order to calculate IDR, the cumulative amount of 
drug dissolved at each time point (mg or moles) normalized by the area of the compact 
(cm2) is plotted against time and linear regression analysis is performed. The slope of this 
line is the IDR and is most often reported as mg/cm2/min or moles/cm2/min. Therefore 
when surface area is held constant, IDR is directly related to the solubility of the drug.  
For this study, the IDR of diastereomer mixtures of three compositions was 
measured. These mixtures were prepared by physically mixing appropriate quantities of 
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Lot 2 crystals (85 % isomer B) and Lot 1 crystals (form AI) to obtain the appropriate 
compositions. The ratio of isomer B to isomer A, that is, NisomerB/NisomerA in the tested 
compositions was 0.25, 1 and 3, where N represents the molar amount of each isomer in 
the mixture. Approximately 120 mg of each diastereomer mixture was placed in a 
stainless steel tablet die (sample holder) and compressed using Instron universal material 
testing system (Model 5869, Norwood, MA) at a speed of 10 mm/min to a maximum 
load of 5 kN to produce a compact of constant area. This particular compression force 
was found to be optimal. Lower compression forces resulted in the formation of compacts 
that showed an initial burst release of drug as they were not well formed, whereas higher 
forces produced fragile disks that fragmented. After compression, the die cavity was 
filled with paraffin wax, such that only one surface of the compact was accessible to the 
dissolution medium. Figure 3.1 shows the experimental set-up used for IDR 
determination. Powder X-ray diffraction analysis of the compacts prior to dissolution was 
carried out and this ensured that the solid form was not altered as a result of compaction. 
The sample holder was then carefully placed in 300 ml of 0.07 N hydrochloric acid 
dissolution medium maintained at 37±0.5 °C. A constant surface area of the compact was 
exposed to the dissolution medium. The surface area of the compacts exposed to the 
dissolution medium were between 0.833–0.836 cm2. The dissolution medium was stirred 
with a paddle placed at a distance of 2.5 cm directly above the compact surface at a 
rotation speed of 55 rpm. Dissolution studies were carried out using a VanderKamp 600 
dissolution apparatus (VanKel Industries, USA). Samples (4 ml) were withdrawn at pre-
determined time intervals, filtered using a 0.2 µm polypropylene syringe filter and 
analyzed using the validated UV spectroscopic assay method. The test for adsorption of 
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drug to the filters revealed no significant loss of drug. The volume of sample withdrawn 
was replaced with an equal volume of pre-equilibrated medium to maintain sink 
conditions. The IDR was determined from the slope of the linear portion of the amount 
dissolved per unit area (moles/cm2) vs. time plot and is reported as the mean of the slope 
of three replicate determinations 
 
 
 
 
 
 
 
 
 
The observed IDR values for the three diastereomer mixtures with NisomerB/NisomerA 
ratios of 0.25, 1 and 3 were compared to the dissolution rate values obtained by 
application of the Higuchi model for a binary mixture of interacting solids.11, 12 
Calculation of dissolution rate by the Higuchi model requires knowledge of the 
solubilities of both crystalline diastereomers, which were measured by solubility studies 
(Section 3.2.3), and diffusion coefficient of the drug molecule. The calculation of 
diffusion coefficient requires knowledge of the radius of the drug molecule. The two-
dimensional chemical structure of the molecule was drawn using ChemDraw® (version 
13.0, PerkinElmer. Massachusetts). The radius of the molecule was determined using 
 
 
 
Dissolution medium: 
0.07N aqueous 
hydrochloric acid  
Paddle speed: 55 rpm 
Compact of constant surface area 
Figure 3.1. Experimental IDR set-up. 
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Molecular operating environment (MOE 2013.08, Chemical Computing Group) software. 
The diffusion coefficient was calculated using the Stokes–Einstein equation assuming 
that the CFA molecule is spherical (Equation 3.2)110: 
r
kT
D
6
               (3.2) 
where D is the diffusion coefficient of the molecule (cm2/min), k is the Boltzmann 
constant, T is the absolute temperature, η is the viscosity of the medium and r is the 
radius of the molecule.  
3.3 Results and Discussion 
3.3.1 Ultraviolet (UV) spectroscopic analysis 
The UV assay method was found to be suitable for the quantification of dissolved 
cefuroxime axetil in 0.07 N hydrochloric acid. The calibration curve of absorbance vs. 
concentration (M) is shown in Figure 3.2 at a maximum wavelength (λmax) of 281 nm. 
The developed analytical method was validated according to ICH Q2 (R1) guidelines as 
explained in Section 3.2.2. The results of the validation study are showed in Table 3.1. 
The standard error for the slope and intercept of the linear regression line were  
2.02×10-2 M-1 and 5.01×10-3, respectively. Figure 3.3 shows the calibration curves 
prepared using the commercially available amorphous drug (equimolar mixture of 
diastereomers), Lot 1 crystals and Lot 3 crystals. There was no significant difference 
between the molar absorptivities as determined from slope of the plots indicating no 
significant effect of diastereomer mixture composition upon the absorption spectrum. 
Table 3.2 shows the linear regression lines and the molar absorptivities determined from 
the calibration curves of the various diastereomer mixture compositions 
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Figure 3.2. Regression plot of cefuroxime axetil (CFA) calibration standards. 
 
 
Table 3.1. Validation parameters of ultraviolet (UV) spectroscopic assay method. 
Validation parameters Values 
Linearity and Range  3.99×10-6 to 3.99×10-5 M (R2 ≥  0.999) 
Accuracy and Precision 
CFA conc. 
(M) Intra-day Inter-day 
  
% 
Recovery±SD 
Precision 
(% RSD) 
% 
Recovery±SD 
Precision 
(% RSD) 
1.18×10-5 99.05±1.17 1.26 99.26±0.36 2.41 
2.35×10-5 98.89±1.17 1.11 98.90±0.78 2.46 
3.92×10-5 99.54±0.50 0.5 99.61±0.62 1.79 
LOD 4.49×10-7 M 
LOQ 1.36×10-6 M 
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Figure 3.3. Regression plot of amorphous CFA, Lot 1 crystals and Lot 3 crystals calibration 
standards. 
 
Table 3.2. Equation of linear regression line and molar absorptivities of standard solutions of 
diastereomer mixtures. 
Sample % Isomer B Equation* Molar absorptivity 
(L mol-1cm-1)** 
Lot 1 crystals  0 2.21x+0.0063 2.21×104 
Amorphous CFA 50 2.20x+0.0061 2.20×104 
Lot 3 crystals 75 2.21x+0.0078 2.21×104 
*Obtained by linear regression of the absorbance vs. concentration (×104 M) plot 
** Calculated from the slope of the linear regression plot 
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 Figure 3.4 shows the regression plot of CFA calibrations standards made in a 
lower concentration range from 1.99×10-8 to 4.80×10-7 M. The correlation coefficient 
(R2) was 0.9992 indicating a linear relationship between absorbance and concentration. 
This calibration curve was then used to quantify lower concentrations of dissolved drug 
in the dissolution medium. 
 
 
Figure 3.4. Regression plot of cefuroxime axetil (CFA) calibration standards in a lower 
concentration range. 
3.3.2 Solubility Studies and Phase Solubility Analysis of Diastereomer Mixtures 
The experimentally determined concentration versus time profile for Lot 1 
crystals is shown in Figure 3.5. The concentration reached a constant value after about 
11 h. As the concentration remained constant, that is, there was no decrease in 
concentration following approach of a steady level, it was concluded that form AI of 
isomer A did not convert to a more stable form during the experiment. A decrease in 
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concentration following a peak or steady concentration level suggests a solvent-mediated 
conversion to a stable crystalline form upon dissolution, indicating that the solid form is 
metastable. PXRD analysis of the solid residue remaining after the solubility study 
showed characteristic crystalline peaks for form AI without the presence of any 
additional peaks. This further confirmed that form AI was stable in the time frame of the 
experiment. The equilibrium solubility of Lot 1 crystals was 2.22×10-4 M (±7.76×10-6 M) 
(average± SD of n=3 replicates). 
 
Figure 3.5. Solubility profile of Lot 1 crystals (form AI) crystals of CFA in 0.07 N hydrochloric 
acid at 37±1 °C. The plotted concentrations are an average value of n=3 replicates and the error 
bars represent standard deviation. 
 
  
The phase solubility diagram plotted as the total isomer concentration, that is sum 
of concentration of isomer A and isomer B as a function of the amount (mg) of isomer B 
added to the solution at 37±1 °C is shown in Figure 3.6. The theoretical isomer 
84 
 
concentration (as shown in Figure 3.6) was calculated from knowledge of the amount of 
isomer B added as a 75 % isomer B mixture plus the equilibrium solubility of  Lot 1 
crystals (2.22×10-4 M). As a solid phase consisting of Lot 1 crystals is always present in 
the system, the thermodynamic activity of dissolved isomer A is constant and its 
concentration is equal to equilibrium solubility. 
 
 
Figure 3.6. Phase solubility diagram of isomer B with isomer A (Lot 1, form AI crystals) of CFA 
in 0.07 N hydrochloric acid at 37±1 °C. Segment b-c represents the plateau region. 
With reference to Figure 3.6, it was initially observed that as the amount of 
isomer B added increased from point a to point b, the total isomer concentration also 
increased. This increase occurred up to a certain point (point b), that is, until the total 
measured isomer concentration was 1.39 mg/ml. Further increase in amount of isomer B 
did not produce a corresponding increase in the total measured isomer concentration as 
represented by the plateau level of Figure 3.6 (segment b–c). Therefore, from the 
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ascending portion of the experimental plot in Figure 3.6, it was concluded that isomer B 
added to the system entered the solution phase resulting in an increase in measured 
concentration. Finally, a plateau phase was reached where an increase in amount of 
isomer B did not result in an increase in measured isomer concentration. The solid 
residue remaining was analyzed by 1H-NMR spectroscopy. The NMR spectra showed an 
increase in the area under the quartet peak at a chemical shift value of 7.01 ppm 
(representing isomer B) as increasing amount of isomer B was added, which indicated 
that the solution was saturated with isomer B.107 
Another important feature of the phase solubility diagram of the diastereomers of 
CFA was that the measured concentration (observed concentration plot in Figure 3.6) 
was greater than the calculated theoretical concentration. This indicated the presence of 
an interaction, possibly formation of a soluble complex between the diastereomers in 
solution. The following scheme was proposed for the observed phenomenon of solubility 
increase: 
)(sA ⇄ )(aqA               (3.3) 
)()( aqaq BA  ⇄ )(aqAB                          (3.4) 
 )(0 aqA AK                           (3.5) 
 
  aqaq
aq
AB
BA
AB
K                                                                                                               (3.6)  
where )(sA and )(aqA  represent solid phase and solution phase isomer A, respectively. 0AK
is the equilibrium solubility of isomer A in the absence of isomer B. aqB and )(aqAB  are 
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the isomer B and AB complex in solution, respectively. If the total isomer concentration 
at point b is represented by S, then: 
     aqABBAS  00             (3.7) 
where  0B  is the equilibrium solubility of isomer B and  aqAB is the concentration of the 
complex (assuming formation of a 1:1 complex between the diastereomers).  
The ratio of the diastereomers in the solution saturated with both isomer A and 
isomer B was determined by 1H-NMR spectroscopy. The areas of the peaks occurring at 
chemical shift values of 6.89 ppm and 7.01 ppm were integrated and their relative ratio is 
expressed in Equation 3.8 (details of 1H-NMR spectroscopy explained in Chapter 2, 
Section 2.2.2).  
   
    2
3
0
0



aq
aq
ABA
ABB
                                   (3.8) 
Rearranging Equation 3.8 and substituting in Equation 3.7 gives the following: 
   aqAB
AS


5.1
5.2 0                        (3.9)  
As the values of S  and  0A are known, the value of  aqAB was calculated and was 
found to be 0.737 mg/ml or 7.23×10-4 M.  0A  is the equilibrium solubility of Lot 1 
crystals (form AI) (Figure 3.3). Further Equation 3.10 was used to calculate  0B  : 
     aqABAB 5.05.1 00             (3.10) 
The value of  0B was calculated to be 0.536 mg/ml or 1.05×10-3 M. 
87 
 
         The values of solubilities of isomer A, isomer B and the resulting concentration of 
the proposed AB complex were then used to calculate the equilibrium constant for the 
formation of the complex using Equation 3.6. 
3.3.3 Intrinsic Dissolution Rate Studies of Diastereomer Mixtures and Application of 
Higuchi Model 
          Based on the results of phase solubility analysis of CFA diastereomers it was 
ascertained that the diastereomers interacted in solution (Section 3.3.2). The intrinsic 
dissolution rate (IDR) of Lot 1 crystals (form AI) as well as diastereomer mixtures of 
three different compositions, with NisomerB/NisomerA ratios of 0.25, 1 and 3 were measured 
using the stationary disk set-up as shown in Figure 3.1. Figure 3.7 shows a 
representative IDR plot of Lot 1 crystals which also represents NisomerB/NisomerA ratio of 0. 
Representative IDR plots of diastereomer mixtures are shown in Figure 3.8. The linear 
regression equations of the plot of amount dissolved per unit area (moles/cm2) versus 
time (min) for Lot 1 crystals and diastereomer mixtures is shown in Table 3.3. 
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Figure 3.7. Representative intrinsic dissolution rate (IDR) plot of the amount dissolved per unit 
area (moles/cm2) versus time (min) of Lot 1 crystal compacts with a fixed surface area of  
0.836 cm2 in 0.07 N hydrochloric acid at 37±1 °C.  
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Figure 3.8. Representative intrinsic dissolution rate (IDR) plot of the amount dissolved per unit 
area (mole/cm2) versus time (min) of diastereomer mixtures of different compositions with a 
fixed surface area of 0.836 cm2 in 0.07 N hydrochloric acid at 37±1 °C. 
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Table 3.3. Regression equations of the amount dissolved per unit area (moles/cm2) versus time 
(min) plot of Lot A1 crystals and various diastereomer mixtures. 
 
*Equation obtained by linear regression of the plot of amount dissolved (moles/cm2) versus time 
(min) 
**IDR is the slope of the plot of amount dissolved per unit area (moles/cm2) versus time (min) 
and is represented as average (±S.D.) of at least n=2 replicates at each diastereomer composition 
 
The plots of amount dissolved per unit area versus time were linear with 
correlation coefficients of R2≥ 0.994 for all the runs (Table 3.3). The linearity of the plots 
(Figure 3.7 and Figure 3.8) indicated that the crystalline diastereomers were physically 
stable during the time frame of the experiment. Solvent-mediated phase conversion to 
crystalline forms with greater stability (and lower solubility) or saturation of the 
dissolution media (absence of sink condition) would be indicated by a curvature in the 
IDR plot. PXRD analysis of the compacts after the dissolution study showed that the 
crystalline peaks corresponding to form AI and form BI were preserved. Therefore 
Composition of 
mixture 
(NisomerB/NisomerA) 
Regression equation* Correlation 
coefficient 
(R2) 
IDR (moles/cm2/min)** 
 
0 (Lot 1 crystals) 
1.32×10-8x-2.39×10-8 > 0.999  
1.30×10-8 (±2×10-10) 1.28×10-8x+2.61×10-8 0.999 
1.30×10-8x+2.06×10-8 >0.999 
 
0.25 
1.80×10-8x-1.17×10-8 >0.999  
1.80×10-8 (±1.20×10-10) 1.79×10-8x-7.60×10-9 0.999 
1.80×10-8x-4.19×10-8 0.994 
 
1 
3.83×10-8x-1.33×10-7 >0.999  
3.89×10-8 (±8.04×10-10) 3.94×10-8x+1.94×10-8 >0.999 
 
3 (Lot 3 crystals) 
1.06×10-7x-6.15×10-9 0.999  
1.05×10-7 (±1.28×10-5) 1.06×10-7x+1.49×10-8 0.998 
1.04×10-7x-8.49×10-8 0.999 
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PXRD analysis provided further confirmation of the absence of any solvent-mediated 
conversion of the crystalline diastereomers. 
The Higuchi model describing dissolution of interacting components, that is, 
components that interact in solution to form a complex (discussed in detail in Chapter 1: 
Section 1.2.3) was used to calculate the theoretical dissolution rates of diastereomer 
mixtures of different compositions. The model was chosen based on evidence of 
interaction between the diastereomers in solution from the phase solubility study (Section 
3.3.2).  
The calculation of theoretical dissolution rate of mixtures using Higuchi model 
requires knowledge of the diffusion coefficients of the molecule and complex as well as 
thickness of the diffusion layer (h term) (Equations 1.22–1.27, Chapter 1: Section 
1.2.3).11, 12 The diffusion coefficient of CFA molecule was calculated using the Stokes-
Einstein equation (Equation 3.2).  The radius of a single CFA molecule was measured to 
be 8.32 Å using MOE software. The diffusion coefficient of the complex was calculated 
by assuming that the radius of the complex is twice that of a single molecule or 16.64 Å. 
The viscosity value of 0.07 N hydrochloric acid was assumed to be the same as that for 
water at 37 °C which is 7.19×10-4 Pas.111 Based on these values, the diffusion coefficient 
for CFA and the CFA complex at 37 °C were 2.28×10-4 cm2/min and 1.14×10-4 cm2/min, 
respectively.  
 The theoretical thickness of the diffusion layer (h term), was calculated by 
rearranging Equation 3.1 to solve for h. The data from the IDR study of Lot 1 crystals 
(Table 3.2) was used to calculate the h value, as the equilibrium solubility (Cs) of Lot 1 
crystals was measured to be 2.22×10-4 M (Section 3.3.2) and the diffusion coefficient of 
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CFA was calculated as 2.28×10-4 cm2/min. The thickness of the diffusion layer was 
calculated to be 39 µm. In previous studies, the thickness of the diffusion layer was found 
to be 30 µm under similar conditions.12,112 
 A knowledge of values of solubilities of Lot 1 crystals (form AI), isomer B as 
well as the complex as determined from the phase solubility studies, the diffusion 
coefficients of CFA and the complex and the thickness of the diffusion layer enabled 
calculation of the critical ratio. The critical ratio is the particular mixture composition at 
which both diasteromers coexist on the compact surface (explained in detail in Chapter 
1: Section 1.2.2). The critical ratio was calculated for NisomerB/NisomerA to be 2.44, where 
NisomerB and NisomerA are the respective amounts of isomer B and isomer A in the mixture. 
Therefore at the critical ratio, NisomerB was 0.71 and Nisomer A was 0.29. For mixture 
compositions of NisomerB> 0.71, isomer B forms the surface phase represented by Case 2 
in Figure 1.5, Chapter 1. The dissolution rate of isomer B (RB) was calculated using 
Equation 1.24 (Chapter 1) where isomer B is component B and isomer A is component 
A. Accordingly the intrinsic dissolution rate of isomer A (RA) was calculated using 
Equation 1.25 for compositions of NisomerB> 0.71. Similarly for compositions where 
NisomerB< 0.71which is represented by Case 3 in Figure 1.5, Chapter 1, isomer A forms 
the surface phase. The intrinsic dissolution rate of isomer A (RA) was calculated using 
Equation 1.22 and that of isomer B (RB) was calculated using Equation 1.23.
11, 12 
 Figure 3.9 shows the intrinsic dissolution rates of diastereomer mixtures with 
values of NisomerB from 0 to 1. These values were calculated as described above using the 
Higuchi model for components that interact in solution.11, 12  The values for the theoretical 
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intrinsic dissolution rates for various diastereomer compositions according to Higuchi 
model for interacting components are listed in Table 3.4. 
 
 
 
 
 
Figure 3.9. Theoretical intrinsic dissolution rates of isomer A and isomer B from diastereomer 
mixtures of various compositions. Values obtained by application of Higuchi model for binary 
mixtures of interacting components. The (*) indicates the critical mixture ratio where NisomerB 
0.71and NisomerA is 0.29.11, 12 
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Table 3.4.Theoretical dissolution rate values of isomer A and isomer B from diastereomer 
mixtures. Values were obtained by application of Higuchi model for components exhibiting 
solution interaction.11, 12 
 
NisomerB/NisomerA NisomerB IDR of isomer B 
(RisomerB×10
8) 
(moles/cm2/min) 
 
IDR of isomer A 
(RisomerA ×10
8) 
(moles/cm2/min) 
 
0 0 - 1.30 
0.11 0.1 0.148 1.33 
0.25 0.2 0.346 1.38 
0.43 0.3 0.623 1.46 
0.67 0.4 1.04 1.56 
1 0.5 1.74 1.74 
1.5 0.6 3.14 2.09 
2.33 0.7 7.41 3.18 
2.44 * 0.71 8.31 3.41 
3 0.75 7.82 2.61 
4 0.8 7.34 1.84 
9 0.9 6.66 0.740 
*indicates critical ratio 
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 The observed IDR values of the diastereomer mixtures of compositions 
represented by NisomerB/NisomerA values of 0.25, 1 and 3 (Table 3.3) were compared with 
the theoretical values for mixtures (calculated using the Higuchi model) given in Table 
3.4. Figure 3.10 shows the comparison of the theoretical and observed IDR of 
diastereomer mixtures of the above mentioned compositions. Based on these results it 
was concluded that the Higuchi model describing the dissolution rate of interacting 
components provided a reasonable fit to the observed IDR data, with the difference in the 
experimental and theoretical rates being less than 10 % for each mixture composition.  
 
 
Figure 3.10. Comparison of IDR values calculated using the Higuchi model for interacting 
components (theoretical) and observed values for diastereomer mixtures. The observed values 
represent the average value of IDR from at least n=2 replicates at each diastereomer mixture 
composition and error bars are the standard deviations. 
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3.4 Conclusion 
 Phase solubility analysis on diastereomers of CFA showed evidence of interaction 
or complexation between the diastereomers in solution. The measured concentration of 
the dissolved diastereomers was greater than the theoretical concentration indicating 
formation of a soluble complex. A scheme was proposed for formation of a soluble 
complex between the diastereomers. The results of the phase solubility study were further 
confirmed by intrinsic dissolution rate measurements on compacts of diastereomer 
mixtures. The dissolution rates of the diastereomers from the mixtures were in good 
agreement with the Higuchi model for dissolution of binary mixtures of components that 
form a 1:1 complex in solution. As CFA suffers from solubility problems, interaction or 
complexation between the diastereomers is an important finding as it implies that using a 
combination of the diastereomers is beneficial over use of a single isomer. Further the 
ratio of the diastereomers expressed as NisomerB/NisomerA that shows the maximum 
dissolution rate when calculated using the Higuchi model for interacting components was 
2.44. Using this composition in formulations may limit dissolution rate-limited 
bioavailability problems of the drug. 
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Chapter 4: Interactive Mixtures for Dissolution Rate Enhancement of 
Cefuroxime Axetil 
4.1 Introduction 
This work involved preparation of mechanically stable interactive mixtures of 
amorphous CFA with an aqueous soluble carrier material and investigation of the 
mechanism of dissolution rate enhancement from interactive mixtures relative to physical 
mixtures and drug agglomerates. To this end, a dissolution model relevant to 
heterogeneous particle distributions was applied to mixture dissolution data (explained in 
detail in Chapter 1: Section 1.4.5).  As amorphous drugs can potentially convert to 
stable crystalline forms during dissolution resulting in variable dissolution profiles, a 
stable crystalline form of CFA was micronized and formulated into an interactive 
mixture.  Modeling the dissolution data enabled calculation of the surface area of drug 
that was available for contact with the dissolution medium or the effective surface area 
and the weight-fraction of agglomerated particles in the mixtures.  Parameters related to 
particle size of agglomerated and dispersed particles in interactive and physical mixtures 
were also calculated in order to understand the mechanism of dissolution rate 
enhancement upon interactive mixing. 
4.2 Materials and Methods 
4.2.1 Materials 
 Commercially available (as received) cefuroxime axetil (Dhanuka Laboratories, 
Mumbai, India) and Lot 3 crystals which is a diastereomer mixture containing 75 % 
isomer B (present as form AI and form BI, Chapter 3: Section 3.2.1) were formulated 
separately as mixtures with sucrose carrier particles. Crystalline sucrose (Lot no. 08189, 
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Fisher Scientific, Fair Lawn, New Jersey) was used as a carrier material. Sucrose was 
chosen as a carrier based on its high aqueous solubility such that it would dissolve rapidly 
in the dissolution medium. Hydrophilic polymers were avoided based on their effect on 
solution viscosity that would further cause a barrier for dissolution. Specific size fractions 
of the drug agglomerates and carrier material were obtained by sieve classification using 
a set of standard sieves (Gilson Company, Inc.). Hydrochloric acid (36 % w/w aqueous 
solution, Lot no. A25X018, Alfa Aesar, Shore Road, Lancashire) and deionized water 
were used to prepare 0.07 N hydrochloric acid as the dissolution medium which was 
degassed prior to use. 
4.2.2 Characterization of CFA and Carriers 
 Commercially available CFA was analyzed by powder X-ray diffraction (PXRD) 
and differential scanning calorimetry (DSC) techniques in order to characterize the solid 
form. PXRD patterns were recorded at room temperature on a X’Pert Pro MPD system 
(P’Analytical B.V., Almelo, the Netherlands) equipped with a with a copper anode  
(λ = 1.5406 Å) and an X’Celerator™ detector. The operational voltage and amperage 
were set to 45 kV and 40 mA, respectively. The radiation was passed through a nickel 
filter. The incident and diffracted beam optics consisted of a divergence slit, antiscatter 
slit (2 °), and soller slit (0.1 mm). Samples were mounted on a back-filled, aluminum 
sample holder and were analyzed in continuous mode with a step size of 0.0170 °2θ and a 
step time of 31.75 s over the range of 2-60 °2θ. The samples were rotated on a vertical 
stage at 16 rpm during the measurements. Diffractograms were analyzed by X’Pert 
HighScore Plus software. DSC measurements were performed using a TA Q100 
differential scanning calorimeter (TA Instruments, Newcastle, DE). Approximately 4 mg 
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samples were placed in aluminum sample pans and hermetically sealed. The 
measurements were made between 0 °C and 250 °C at a scan rate of 20 °C/minute under 
a constant nitrogen purge (50 ml/min). Data were analyzed using TA Instruments 
Universal Analysis software (version 4.5A). Lot 3 crystals were characterized using 
PXRD analysis as described in Chapter 2: Section 2.2.3.  
Particle size distributions of the commercially available drug and carrier materials 
were determined using sieve analysis as per USP 32/NF 27 chapter <786> using 
approximately 10 g of each material for the test.113A light microscope (Model BX-51, 
Olympus) was used to visualize primary drug particles within agglomerates, and the 
particle sizes were based on the Feret diameters (ImageJ software, version 1.41o). Lot 3 
crystals were milled using a ball mixer mill (Retsch mill, MM200, Haan, Germany). 
Approximately 1 g of material was sealed in the milling vessel and the material was 
ground at an impact frequency of 15 Hz for 30 min. Particle size analysis was carried out 
on the milled material using optical microscopy and the particle sizes were based on the 
Feret diameters.  
The true volumes of commercially available CFA and Lot 3 crystals were 
determined using a stereopycnometer (Model SPY-6DC, Quantachrome Instruments, 
Boynton Beach, FL) using helium as the displaced gas. Samples weighing approximately 
5 g were purged with nitrogen for 20 min before measurement. True density was 
calculated as the ratio of the sample weight to the true volume.  
Specific surface areas of the drug materials used to prepare the mixtures were 
measured by multi-point BET (Brunauer, Emmett and Teller) analysis of nitrogen vapor 
adsorption (FlowSorb II 2300, Micromeritics Instrument Corporation, Norcross, GA). 
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Powder samples were dried under vacuum at 50 °C for 48 h. Each dried powder was then 
filled into a clean, dry sample tube and degassed under a helium purge at 50 °C for 6 h. 
Measurements were made at a series of relative nitrogen pressures (p/p0) of 0.05, 0.10, 
0.15, 0.20 and 0.25 by taking two adsorbed volume () measurements per sample at each 
relative pressure. The BET equation (Equation 4.1) was used to compute the volume of 
gas required to form a monolayer ( mv ): 
cv
pp
cv
c
ppv
pp
mm
1
)/(
1
)/1(
/
0
0
0 



                      (4.1) 
Linear regression analysis was used to estimate mv  and the affinity constant, c . 
The total surface area of the sample ( )S  was computed using the following equation: 
M
ANv
S m              (4.2) 
where A is Avogadro’s number, N is the area of each adsorbed nitrogen gas molecule 
(16.2 Å2) and M is the molar volume of the gas. The total surface area was divided by the 
mass of the sample to obtain the specific surface area (SSA) of each sample.114 
4.2.3 Intrinsic Dissolution Rate (IDR) Measurement 
Intrinsic dissolution rate (IDR) of commercially available CFA was measured 
using the experimental set-up and the method as described in Chapter 3: Section 3.2.4. 
The value for IDR of Lot 3 crystals is reported in Chapter 3: Table 3.2 and this value 
was used for further calculation in this study.  
4.2.4 Drug-Carrier Mixture Preparation 
Mixtures of CFA drug agglomerates (< 53 µm size fraction) and Lot 3 crystal 
milled particles were prepared separately with a specific size fraction of the carrier 
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material, sucrose in the 500–1000 µm size range, using a centrifugal planetary mixer 
(Thinky Mixer ARM-310, Thinky USA, Inc.).  Briefly, 5 g of each 10 % w/w CFA-
carrier material mixture was prepared by weighing out appropriate quantities of each 
component, followed by mixing at a rotational speed of 2000 rpm for 5 min. All materials 
were stored at 33 % RH in a humidity chamber for 72 h prior to use. Mechanical stability 
of the mixtures was assessed by sieving them until a constant weight (less than 2 % 
weight difference) remained on a sieve whose size opening was smaller than the carrier 
particles but was larger than the original drug particles. Figure 4.1 shows the 
experimental set-up of the sieves used for mechanical stability determination of mixtures. 
Mixtures were also evaluated using microscopy to visualize the mixtures. The content of 
drug retained in each mixture was determined by analyzing 6 × 20 mg samples with the 
validated UV assay method (Chapter 3: Section 3.3.1).  Mixtures using the same size 
fractions of the drug and carrier material were also prepared using a laboratory scale V-
blender and were similarly examined by optical microscopy. 
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Figure 4.1. Experimental set-up of sieves for mechanical stability determination of mixtures; light 
blue-carrier particles, dark blue-drug particles. 
4.2.5 Dissolution Studies 
Dissolution studies were carried out on pure drug, physical mixtures and 
interactive mixtures of the drug with sucrose carrier particles.  The amount of mixture 
used for the dissolution study contained the equivalent of approximately 90 mg of drug 
and each mixture sample was analyzed in triplicate. Mixture samples were placed in the 
basket assembly and were immersed in 900 ml of 0.07 N hydrochloric acid as the 
dissolution medium. The choice of the dissolution medium was based on USP 
specifications for dissolution medium for CFA tablets.115 The rotation speed and bath 
temperature were maintained at 50 rpm and 37±0.5 °C, respectively (Vanderkamp 600 
dissolution tester, VanKel Industries, Inc.). Samples (5 ml) were withdrawn at pre-
determined time intervals, filtered through 0.2 µm polypropylene filter, appropriately 
diluted if necessary and analyzed for CFA content by a validated UV spectroscopic assay 
method at a λmax of 281 nm (Chapter 3: Section 3.3.1). The volume of sample 
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withdrawn at each time point was replaced with an equal volume of blank dissolution 
media. 
4.2.6 Modeling of Dissolution Data 
Drug dissolution from interactive mixtures has been modeled using the 
biexponential equation derived from Wagner’s model assuming exponential surface area 
changes as dissolution proceeds.96  This model treats dissolution from interactive mixtures 
as a two-stage process involving rapid dissolution of dispersed particles in parallel with 
slower dissolution of agglomerated particles as illustrated in Figure 4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The biexponential dissolution model (Equation 1.45, Chapter 1: Section 1.4.5) 
was used to model drug dissolution from pure drug agglomerates, interactive and 
 
 
 
Carrier is dissolved in 
dissolution medium 
Agglomerated particles W
a
 
ka kd
 
Drug in solution 
 
Dispersed particles W
d
 
 
Figure 4.2.Schematic representation of drug dissolution from interactive mixtures; light blue-
carrier particles, dark blue-drug particles. 
Drug in solution 
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physical mixtures with sucrose. This model has shown utility in studying dissolution 
from drug particles that have bimodal size distributions in numerous studies.91-94  The 
method of residuals was used to determine the various parameters, such as ka, kd, Wa and 
Wd that describe the dissolution of the dispersed and agglomerated particles. This model 
assumes a five-fold difference between the rate constants.116  
The parameters obtained through application of the biexponential model to 
dissolution data enabled calculation of the effective surface area of the agglomerated and 
dispersed particles, namely, Sa and Sd respectively. Equation 1.41 (Chapter 1: Section 
1.4.5) is an expression for the amount of drug dissolved at t=∞. Therefore W∞ is the 
amount of drug dissolved at infinite time or the initial amount of drug. In case of the 
biexponential model, Wa is the initial amount (or weight) of drug present as agglomerates 
in the mixture and can be expressed by Equation 4.3 which enabled calculation of the 
effective surface area of the agglomerated particles in the mixture (Sa): 
s
aa
a
kC
kW
S                (4.3) 
 In Equation 4.3, the term kCs is the intrinsic dissolution rate which was measured 
experimentally using the stationary disk method (Section 4.2.3), and Wa and ka were 
calculated following application of the method of residuals to the amount remaining to 
dissolve versus time data. The effective surface area of the dispersed particles in the 
mixtures, Sd was calculated using Equation 4.4: 
s
dd
d
kC
kW
S                                      (4.4) 
 Therefore Equation 4.3 and Equation 4.4 allowed the effect of interactive 
mixing on the amount of interface between the particles and the dissolution medium to be 
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determined and allowed comparisons to be made between the effective surface areas 
contributing to dissolution from the various samples.  
 Further modeling also involved development of a relationship between the rate 
constants, ka and kd describing the surface area changes of the agglomerated and 
dispersed particles and a parameter related to particle size. Assuming that the 
agglomerated particles are spherical, the initial weight of ‘n’ number of agglomerated 
particles can be expressed as: 
nrW aaa  
3
3
4
             (4.5) 
where is ra the radius of the agglomerated particles, ρa is the density of the agglomerated 
particles. The surface area of ‘n’ number of agglomerated particles is given by: 
nrS aa 
24               (4.6) 
Substitution of Equation 4.5 and Equation 4.6 in Equation 4.3 gives the following 
a
s
aa
k
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r
3
               (4.7) 
where raρa is a parameter related to the particle size of the agglomerated particles. 
Similarly for dispersed particles, the relationship between the parameter related to 
particle size and rate constant is as follows: 
d
s
dd
k
kC
r
3
               (4.8) 
4.2.7 Statistical Analyses 
 Dissolution profiles of drug agglomerates, physical and interactive mixtures were 
compared using the similarity factor (f2). The similarity factor is a logarithmic reciprocal 
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square root transformation of the sum of the squared error and is a measurement of the 
‘sameness or equivalence” of two dissolution profiles (Equation 4.9).117 
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where Rt is the mean percent drug dissolved of a reference product and Tt  is the mean 
percent drug dissolved of a test product and n is the number of time points. f2 values of 
50–100 indicate that the dissolution profiles are similar. An f2 value of 50 indicates an 
average difference between mean dissolution profiles of up to 10 %.117 In order to 
calculate the f2 value, the mean cumulative percent dissolved value was used from n=3 
measurements for each mixture sample. Calculation of similarity factor (f2) value allows 
an appropriate weighting to be given to certain time points of the dissolution profile.  
One-way analysis of variance (ANOVA) with Tukey’s multiple comparison test 
was employed to evaluate the statistical significance between the various parameters 
calculated by application of the method of residuals to amount remaining to dissolve 
versus time data for the mixture samples (α = 0.05). Two-way ANOVA with Tukey’s 
multiple comparison tests was used to evaluate statistical significance between 
parameters and well as any statistically significant interactions calculated for the mixture 
samples containing two different coating materials. In two-way ANOVA, the factors 
were the coating material (Amorphous CFA vs. Lot 3 crystals (milled)) and mixture type 
(pure drug, physical mixtures and interactive mixtures). 
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4.3 Results and Discussion 
4.3.1 Solid State, Particle Size and Surface Area Analysis of CFA 
The PXRD pattern of commercially received CFA (Figure 4.3) revealed a broad 
diffuse pattern characteristic of amorphous solids The DSC thermogram for the drug 
exhibited a glass transition (Tg) event at 78.1 °C (Figure 4.4) which indicated that the 
supplied drug material was the amorphous solid form. The reported Tg for amorphous 
CFA is 77.5 °C.118 
 
Figure 4.3. PXRD pattern of commercially available CFA. 
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Figure 4.4. DSC thermogram of commercially available CFA at a heating rate of 20 °C/min. 
 
Lot 3 crystals mixture (75 % isomer B) was prepared by physically mixing 
appropriate quantities of Lot 2 crystals containing 85 % wt. isomer B and Lot 1 crystals. 
The solid forms of CFA diastereomers present in Lot 3 crystals were form AI and form 
BI.  
 The particle size distribution of sucrose was determined using a set of standard 
sieves. The largest size fraction (32 % w/w) of the sucrose particles was the  
500–1000 µm size range. Figure 4.5 is an optical microscopy image of sucrose carrier 
particles that were used to prepare physical and interactive mixtures.  
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Figure 4.5. Optical microscopy image of sucrose carrier particle (500–1000 µm). Images obtained 
under 10  magnification. 
 
Figure 4.6a is the histogram for particle size analysis of commercially available 
CFA by sieve analysis. Optical microscopy of CFA particles (< 53 µm size range 
collected by sieve analysis) revealed the presence of the drug agglomerates (Figure 
4.6b). In order to obtain information on the particle size of the dispersed particles in the 
< 53 µm agglomerate size fraction, the agglomerates were dispersed in oil and the 
particles visualized by optical microscopy. Figure 4.6c is the image of the material 
dispersed in oil. The d30, d50 and d90 values found using image analysis were 10 μm,  
20 μm and 40 μm, respectively, by measuring the Feret diameter of approximately 1200 
particles. Drug particles in the < 53 µm size range (using sieve analysis) were used to 
form interactive and physical mixtures with both carrier particles. 
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Figure 4.6. (a) Particle size analysis of commercially available CFA obtained by sieve analysis as 
per USP 32/NF 27 <786> method (b) Optical microscopy image of fine particles (< 53 µm size 
fraction) from the commercially available CFA showing the presence of agglomerates (c) Optical 
microscopy image of fine particles (< 53 µm size fraction) from the commercially available CFA 
dispersed in oil showing primary particles. Images obtained under 10  magnification. 
 
Figure 4.7a and Figure 4.7b are the optical microscopy images for milled 
particles of Lot 3 crystals before and after dispersion in oil, respectively. The Feret d30, 
d50 and d90 values were found to be 3.8 μm, 5.7 μm and 28 μm for the milled particles and 
1.6 μm, 4 μm and 15 μm for the milled particles following dispersion in oil. PXRD 
analysis of the milled particles showed preservation of crystalline peaks of form AI and 
form BI indicating absence of phase conversion upon milling (Figure 4.8).103 
 
 
 
b 
c
b 
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Figure 4.8. PXRD pattern (a) Milled particles of Lot 3 crystals (75 % isomer B) (b) Reported 
pattern of form AI (c) Reported pattern of form BI.104 
  
Figure 4.7. Optical microscopy images of Lot 3 crystals (75 % isomer B) (a) without dispersion in 
oil (b) after dispersion in oil. Images obtained under 10  magnification. 
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The true density of commercially available CFA (< 53 μm) size fraction was  
1.04 g/cm3 and that of Lot 3 crystals (milled) was 1.44 g/cm3. 
Figure 4.9 and Figure 4.10 are the BET plots used to measure the specific 
surface area (SSA) of the drug materials used. The value of specific surface area, as 
determined by nitrogen vapor adsorption, represents the theoretical maximum surface 
area of the drug particles that is available for contact with solvent during dissolution. The 
total surface area was calculated using Equation 4.2 (Section 4.2.2) following 
application of the BET equation for each sample and this value was divided by the 
sample mass to obtain the specific surface area (SSA). Table 4.1 shows the SSA values 
in m2/g for each CFA sample. 
 
 
Figure 4.9. Representative BET plot of commercially available CFA (< 53 µm) size fraction. 
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Figure 4.10. Representative BET plot of milled particles of Lot 3 crystals. 
 
 
 
Table 4.1. Specific surface area values of drug materials used to coat carrier particles. Values 
represent average (± SD) of n=2 measurements. 
 
Sample Specific surface area (m2/g) 
Commercially available amorphous CFA (< 53 μm) size 
fraction 
0.167 (±5×10-4) 
Milled particles of Lot 3 crystals (75 % isomer B) 0.881 (±3.50×10-3) 
 
 
4.3.2 Intrinsic Dissolution Rate (IDR) Profile of Amorphous CFA 
The entire dissolution profile of commercially available amorphous CFA in  
0.07 N hydrochloric acid solution at 37 °C expressed as amount dissolved per unit area 
(mg/cm2) vs. time (min) is shown in Figure 4.11a. It was observed that the initial portion 
of the plot was linear, followed by a gradual curvature or decrease in slope. The decrease 
in slope could be attributed to phase transformation of amorphous CFA to a more stable, 
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less soluble solid form during dissolution. In order to determine the linear portion for 
determination of IDR, the first derivative was calculated and the data were considered 
linear when this value showed less than 15 % variation. A residuals plot was also 
constructed and the residuals were found to be random up to 60 min time point followed 
by a pattern which is indicative of non-linearity in the data. The IDR of amorphous CFA 
was taken as the slope of the initial linear segment of the amount dissolved per unit area 
vs time plot as shown Figure 4.11b. Table 4.2 shows the regression equations of the 
initial linear segment of the amount dissolved per unit area (mg/cm2) versus time (min) 
plot of amorphous CFA. 
Non-linear IDR profiles as shown in Figure 4.11a are typical for amorphous 
solids and metastable polymorphs that undergo solvent-mediated transformations to more 
stable and less soluble crystalline forms during dissolution.119-121 PXRD analysis was 
used to confirm that the non-linearity in the IDR plot was caused by phase conversion of 
amorphous CFA during the dissolution experiment. PXRD analysis of the compacts was 
performed both prior to and after the IDR measurement. Figure 4.12a is the powder 
diffractogram of the compact before the dissolution experiment which shows a diffuse 
pattern characteristic of amorphous solids. The PXRD pattern of the compact after the 
dissolution experiment shows the presence of Bragg peaks indicating that a crystalline 
material had deposited on the compact surface (Figure 4.12b). These data supported the 
fact that amorphous CFA underwent a solvent-mediated phase transformation to a stable 
crystalline form during dissolution. 
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Figure 4.11. Representative intrinsic dissolution rate (IDR) profile of commercially available 
amorphous CFA (a) entire profile showing curvature (b) initial linear segment up to 60 min used 
to calculate IDR. 
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Table 4.2. Regression equations of the amount dissolved per unit area (mg/cm2) versus  
time (min) plot of amorphous CFA. 
*Equation obtained by linear regression of the initial linear segment of the plot of amount 
dissolved (mg/cm2) versus time (min) (Figure 4.11b) 
**IDR is the slope of the plot of amount dissolved per unit area (mg/cm2) versus time (min) and 
is represented as average (±S.D.) of at least n=2 replicates.  
 
A representative IDR plot for Lot 3 crystals mixture (75 % isomer B: 25 % isomer 
A present as solid form BI and form AI) is shown in Figure 3.8, Chapter 3.  The IDR 
plots were linear indicating that form AI and form BI were physically stable in the 
dissolution medium during the time frame of the experiment. The IDR values of Lot 3 
crystals (NisomerB/NisomerA = 3) was 5.38×10
-2 (±6.53×10-4) mg/cm2/min, this value 
represents the average (±S.D.) of n=3 replicate measurements.  
 Amorphous CFA has a higher IDR and a higher solubility based on the direct 
relationship between IDR and solubility (Equation 3.1, Chapter 3) as compared to Lot 3 
crystals. Therefore, commercial products contain the amorphous solid form of CFA based 
on its higher apparent solubility in an effort to improve dissolution rate. However, the 
results from the IDR study on amorphous CFA compacts showed evidence of solvent-
mediated conversion to a less soluble crystalline form during dissolution. Solvent-
Sample Regression equation* Correlation 
coefficient (R2) 
IDR (mg/cm2/min)** 
 
 
Amorphous CFA 
 
7.67×10-2x+2.27×10-2 
7.56×10-2x+2.92×10-2 
7.73×10-2x-2.24×10-2 
 
> 0.999 
>0.999 
>0.999 
 
 
 
7.65×10-2 (±8.62×10-4) 
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mediated phase transformations can potentially result in non-reproducible dissolution 
profiles from formulations containing the metastable solid form of a drug. Since the 
crystalline forms (form AI and form BI) were physically stable in the dissolution medium 
during the time frame of the study, this work also involved preparation and evaluation of 
interactive mixtures of micronized particles of the stable crystalline form of CFA as a 
means of circumventing the problem of phase conversion during dissolution. 
 
 
 
 
Figure 4.12. PXRD plots of commercially available CFA compacts (a) prior to dissolution study 
(b) after dissolution study showing presence of crystalline diffraction peaks. 
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4.3.3 Evaluation of Interactive and Physical Mixtures: Mechanical Stability, Optical 
Microscopy and Drug Content Analyses 
 Table 4.3 shows the drug content in the various mixtures measured using a 
validated UV spectroscopic assay. The values for drug content in mixtures prepared using 
the laboratory scale V-blender represents the drug content of these mixtures prior to 
sieving. This was because a small fraction, less than 1 % wt. of drug was retained on 
carrier following sieve analysis. Since sieving almost completely separated the mixture 
into its components, the mixtures prepared using the V-blender were used in dissolution 
studies without sieving. The mixture samples prepared using the centrifugal planetary 
mixer (Thinky® mixer) were sieved using the set-up shown in Figure 4.1 prior to 
measurement of drug content. 
Optical microscopy was used in order to visualize the presence of any interactions 
between the drug and carrier particles. Figure 4.13a and Figure 4.13b are the optical 
micrographs of the mixtures of the drug-sucrose mixtures prepared using the Thinky® 
mixer. Figure 4.13c and Figure 4.13d are the optical micrographs of the drug-sucrose 
mixtures prepared using the V-blender. Figure 4.13a and Figure 4.13b clearly showed 
that the drug particles were adhered to the carrier surface supporting evidence for 
formation of mechanically stable interactive mixtures. Figures 4.13c and Figure 4.13d 
showed the presence of agglomerated CFA particles both adhered to, and separate from 
the carrier surface representative of physical mixtures. Thus, sieving and microscopy 
both qualitatively indicated a greater degree of deagglomeration and greater drug-carrier 
interactions in the interactive mixtures compared to the physical mixtures. This can be 
attributed to the high-speed, centrifugal-planetary mixer, which provided much more 
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energy to break down the agglomerates and cause them to adhere to the carrier surface 
than the low intensity, laboratory-scale V-blender. 
Table 4.3.  Drug content in prepared mixtures. Targeted drug content was 10 % wt. drug.  Values 
represent average (% RSD) obtained from 6 samples. 
Mixture sample Drug content 
      (% wt.) 
Amorphous CFA-sucrose interactive mixture* 8.01 (0.99) 
Lot 3 crystals-sucrose interactive mixture* 8.92 (0.86) 
Amorphous CFA-sucrose physical mixture** 8.27 (1.21) 
Lot 3 crystals-sucrose physical mixture** 8.74 (1.22) 
*indicates mixtures prepared using Thinky® mixer. Drug content determined after sieving. 
**indicates mixtures prepared using laboratory scale V-blender. Drug content determined prior to 
mechanical sieving. 
 
 
  
Figure 4.13. Optical micrographs of prepared mixtures (a) amorphous CFA-sucrose interactive 
mixture (b) Lot 3 crystals (milled)-sucrose interactive mixture (c) amorphous CFA-sucrose 
physical mixture (d) Lot 3 crystals (milled) -sucrose physical mixture. All images obtained under 
10  magnification. 
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4.3.4 Dissolution Profiles and Modeling Results 
 Dissolution profiles of amorphous CFA agglomerates and mixtures were obtained 
by adding mixture samples containing approximately 90 mg of drug to 900 ml of 0.07 N 
hydrochloric acid. Figure 4.14 shows the cumulative amount dissolved vs. time for all 
the mixtures and for drug agglomerates. 
 
Figure 4.14. Representative cumulative percent dissolved versus time profiles for amorphous 
CFA agglomerates (< 53 µm), interactive and physical mixtures, thereof, prepared with sucrose  
(500–1000 µm) carrier particles. 
 
 The dissolution profiles for the amorphous CFA agglomerates and the physical 
mixtures with both carriers were similar to each other with approximately 90 % of the 
drug dissolved after about 48 h. In sharp contrast, the interactive mixtures were almost 
completely dissolved in 6 h (Figure 4.14). The calculated similarity factor (f2) values 
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between the dissolution profiles of amorphous CFA agglomerates, physical and 
interactive mixtures with sucrose are given in Table 4.4. 
Table 4.4. Similarity factor (f2) values for amorphous mixture samples. 
Comparison f2 statistic value* Inference 
Amorphous agglomerates and 
physical mixture 
92.52 Dissolution profiles similar 
Amorphous agglomerates and 
interactive mixture 
15.9 Dissolution profiles not 
similar 
Physical mixture and 
interactive mixture 
16.3 Dissolution profiles not 
similar 
*f2 value calculated using Equation 4.9 (Section 4.2.7). f2 values between 50–100 indicate 
similarity between dissolution profiles.116  
  
In order to understand the improvement in dissolution rate of drug from 
interactive mixtures relative to amorphous drug agglomerates and physical mixtures, the 
biexponential model (Equation 1.45, Chapter 1: Section 1.4.5) was applied to the 
amount remaining to dissolve vs. time data. Figure 4.15a is a representative amount 
remaining to dissolve (mg) vs time plot for amorphous CFA-sucrose interactive mixture 
and the biexponential model fit to the data. The method of residuals was used to 
determine Wa and ka from the terminal portion of the plot and the residuals were used to 
calculate Wd and kd as shown in Figure 4.15b.  Table 4.5 shows the equations following 
application of the biexponential model to amount remaining to dissolve vs time data for 
the amorphous CFA mixture samples and the correlation coefficients of the model fitting. 
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The correlation coefficients are greater than 0.994 indicating that the biexponential model 
fit the dissolution data. 
   
 
Figure 4.15. (a) Representative amount remaining to dissolve vs time plot of amorphous CFA-
sucrose interactive mixture (b) Application of method of residuals to amount remaining to 
dissolve vs time plot. 
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Table 4.5. Biexponential model fit to amount remaining to dissolve vs time data for amorphous 
CFA mixture samples. 
Sample Biexponential model equation* 
Correlation 
coefficient (R2) 
 
Amorphous CFA agglomerates 
78.44e-0.00062t+11.33e-0.039t 0.999 
78.35e-0.00062t+11.93e-0.041t 0.999 
78.48e-0.00064t+10.97e-0.040t 0.997 
 
Amorphous CFA-sucrose physical 
mixture 
79.45e-0.00085t+11.83e-0.038t 0.996 
79.45e-0.00085t+11.81e-0.039t 0.996 
80.11e-0.00088t+12.38e-0.041t 0.994 
 
Amorphous CFA-sucrose 
interactive mixture 
31.36e-0.0088t+57.58e-0.041t 0.999 
29.08e-0.0087t+60.54e-0.039t 0.999 
28.79e-0.0087t+63.61e-0.040t 0.999 
*Biexponential model is of the form Wae-
kat+Wde-
kdt 
The initial weights of agglomerated and dispersed particles, Wa and Wd were 
determined which enabled calculation of the weight-fraction of agglomerated particles 
represented by 
da
a
WW
W

 for each mixture sample. Results are shown in Figure 4.16. 
One-way ANOVA with Tukey’s multiple comparison tests were used to evaluate 
statistical significance between the mixtures. 
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Figure 4.16. Comparison of weight–fraction of agglomerated particles for amorphous CFA 
agglomerates (< 53 µm size fraction), interactive and physical mixtures, thereof, prepared with 
sucrose carrier particles based on modeling of dissolution data (Equation 1.45). * # represents 
statistical significant comparisons. Each data point represents the average of n=3 replicates, 
where the error bars are the standard deviation (SD). 
The weight-fraction of agglomerated particles was significantly lower for the 
interactive mixture compared to that of drug agglomerates and the physical mixture 
(p<0.05). The weight-fraction of agglomerated particles in the interactive mixture was 
0.33 (±2.10×10-2) as compared to 0.873 (±4.75×10-3) and 0.869 (±2.48×10-3) for CFA 
agglomerates and physical mixture, respectively. These data indicate that interactive 
mixing was able to decrease agglomeration of drug particles. In contrast, low-intensity 
physical mixing was not able to effectively break up drug agglomerates causing the 
weight-fraction of agglomerated particles to be significantly higher in physical mixtures 
and comparable to that of the pure drug agglomerates. 
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The effective surface area of the agglomerated and dispersed particles, Sa and Sd, 
were calculated from Equation 4.3 and Equation 4.4, respectively. Figure 4.17 shows 
the sum of the Sa and Sd term for amorphous CFA agglomerates and interactive and 
physical mixtures. The sum of the effective surface area of the agglomerated and 
dispersed particles from the interactive mixture was significantly higher compared to that 
of drug agglomerates and the physical mixture (p<0.05). The effective surface area of the 
drug particles from the interactive mixture was 35.3 (±1.40) cm2 as compared to  
6.58 (±0.218) cm2 and 7.08 (±0.353) cm2 for CFA agglomerates and physical mixture, 
respectively. Interactive mixing was able to effectively break up the agglomerated drug 
particles such that a larger fraction of the total surface area was available for dissolution.  
 
Figure 4.17. Comparison of the effective surface areas of agglomerated particles and dispersed 
particles, for amorphous CFA agglomerates (< 53µm size fraction), interactive and physical 
mixtures, thereof, prepared with sucrose carrier particles. Values calculated using Equation 4.3 
and Equation 4.4. * # represents statistical significant comparisons. Each data point represents 
the average of n=3 replicates, where the error bars are the standard deviation (SD). 
126 
 
 
The sum of the effective surface areas of the agglomerated and dispersed 
particles, calculated using Equation 4.3 and Equation 4.4 for the various samples were 
calculated as a fraction of the theoretical maximum surface area available for dissolution. 
The theoretical maximum surface area for each sample was calculated from knowledge of 
the specific surface area (SSA) of CFA agglomerates measured by nitrogen vapor 
adsorption (< 53 μm size fraction, Table 4.1) and the amount of drug used in the 
dissolution experiment. The values of the percent total surface area of the different 
samples are given in Table 4.6.  
 
Table 4.6. Percent total surface area of CFA agglomerates and mixture samples based on 
dissolution data. Theoretical maximum surface area determined using nitrogen vapor adsorption 
analysis. Values represent average (±SD) of n=3 replicates for each sample. 
Sample % Total surface area 
CFA agglomerates 4.45 (±0.127) 
CFA-sucrose physical mixture 4.69 (±0.197) 
CFA-sucrose interactive mixture 2.37E+01 (±0.494)*# 
*# represents statistical significant comparisons; *vs CFA agglomerates and #vs physical mixture 
 
 Based on Figure 4.17 and Table 4.6, it was concluded that interactive mixing was 
able to deagglomerate the particles such that a significantly higher fraction of the total 
surface area of the drug particles were available for dissolution. The mechanism of 
dissolution rate enhancement from interactive mixtures can be attributed to surface area 
increase afforded by high-intensity mixing of the carrier particles with the drug 
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agglomerates causing break down of agglomerated drug particles into dispersed drug 
particles or smaller agglomerates with a larger surface area exposed to the solvent. 
The relationship between the rate constants describing the surface area change 
and a parameter related to particle size was developed using Equation 4.7 and Equation 
4.8 for the agglomerated and dispersed particles, respectively. The values for the 
parameter related to particle size for the agglomerated particles (raρa) for CFA 
agglomerates and a mixture is shown in Figure 4.18 whereas that for the dispersed 
particles (rdρd) is shown in Figure 4.19.  The parameter related to particle size for the 
agglomerated particles was significantly lower for the interactive mixtures compared to 
the CFA agglomerates and the physical mixture. The value of the raρa term for the 
interactive mixture was 26.4 (±0.155) mg/cm2 as compared to 366 (±6.68) mg/cm2 and 
267 (±5.31) mg/cm2 for CFA agglomerates and physical mixture, respectively.  
Comparison of the value for the rdρd term across the mixtures revealed that this 
term was not significantly different for any of the samples (p=0.184). 
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Figure 4.18. Comparison of parameter related to agglomerate particle size (
aar  ) for amorphous 
CFA agglomerates (< 53µm size fraction), interactive and physical mixtures, thereof, prepared 
with sucrose carrier particles based on particle dissolution data. Values calculated using 
Equation 4.7.* # represents statistical significant comparisons. Each data point represents the 
average of n=3 replicates, where the error bars are the standard deviation (SD). 
  
 
129 
 
 
Figure 4.19. Comparison of parameter related to dispersed particle size (
ddr  ) for amorphous 
CFA agglomerates (< 53µm size fraction), interactive and physical mixtures, thereof, prepared 
with sucrose carrier particles based on particle dissolution data. Values calculated using 
Equation 4.8. Each data point represents the average of n=3 replicates, where the error bars are 
the standard deviation (SD). 
The data in Figure 4.18 and Figure 4.19 can be understood as follows: the size of 
the agglomerated particles (described by radius, ra and represented by the raρa term) was 
significantly lower in interactive mixtures as compared to physical mixture and CFA 
agglomerates, caused by break down of the agglomerated drug particles upon impaction 
with the sucrose carrier. In this case, physical mixing also decreased the particle size of 
the agglomerates, although not to the same degree as interactive mixing. The density of 
the agglomerates (represented by the ρa term) would also affect the raρa term; as the 
density of agglomerates with a larger particle size is expected to be lower than those with 
a smaller particle size based on less efficient packing of larger size particles. However the 
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density term is not expected to be significantly different between particles of different 
sizes and as a result particle size would play a more important role in determining the 
value of the raρa term.  
The parameter related to particle size of dispersed particles, rdρd term was not 
significantly different across the samples (Figure 4.19) indicating that interactive mixing 
did not appear to affect the size of the dispersed particles. This indicated that there was 
no milling or particle size reduction of the drug during mixing. The concepts relating the 
parameter related to particle size of agglomerated and dispersed particles in the samples 
are depicted in Figure 4.20. 
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Figure 4.20. Schematic representation of parameter related particle size (rρ term) in CFA drug 
agglomerates, physical and interactive mixtures: pink-carrier particles; blue-micronized drug 
particles. The black circles represent the particle size. 
Equation 4.7 and Equation 4.8 were used to calculate the radius of the 
agglomerated and dispersed particles, respectively. The density value used in these 
equations was the true density of the material as measured by helium pycnometry. The 
radius of the agglomerated particles for the amorphous CFA-sucrose interactive mixture 
was calculated as 254 (±1.49) μm and that of the dispersed particles was  
54.76 (±1.37) μm. These values were compared to the radius of the particles calculated 
using the specific surface area (SSA) of amorphous CFA (< 53 μm) size fraction and the 
true density of the material. The value of the radius using the vapor adsorption analysis 
method was 17.06 μm which represents the size of the dispersed particles. The 
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significantly lower value of particle size of the dispersed particles calculated using vapor 
adsorption analysis as compared to that calculated from the dissolution data may be 
attributed to the surface roughness of amorphous CFA particles. An increase in surface 
roughness may have increased the value of SSA leading to an underestimation of particle 
size. 
The results of modeling of the dissolution data for CFA agglomerates and the 
mixtures prepared with sucrose carrier particles, showed that interactive mixing was able 
to decrease the weight-fraction of agglomerated particles. The dissolution rate 
enhancement upon interactive mixing was attributed to an increase in effective surface 
area of the drug exposed to the solvent when formulated as an interactive mixture. The 
increase in effective surface area was caused by a decrease in agglomerate particle size 
by break down of the agglomerates upon impaction with the carrier particles during 
mixing. Based on dissolution rate enhancement of amorphous CFA following 
formulation as an interactive mixture, this work was extended to include preparation of 
interactive mixtures of crystalline forms of CFA.  
As amorphous CFA is prone to solvent-mediated phase transformation to stable 
crystalline forms during dissolution, milled particles Lot 3 crystals (diastereomer eutectic 
mixture containing 75 % isomer B: 25 % isomer A) were formulated as interactive 
mixtures with sucrose carrier particles. It was hypothesized that formation of interactive 
mixtures of micronized particles of these more physically stable solid forms would 
enhance the dissolution rate enough to compensate for their lower solubility relative to 
amorphous CFA and avoid the problem of solvent-mediated phase transformation. This 
particular diastereomer ratio containing 75 % isomer B and 25 % isomer A was chosen, 
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as the ratio of NisomerB/NisomerA in this mixture is close to the critical mixture ratio of 2.44 
which shows the highest dissolution rate (Figure 3.9, Chapter 3). Figure 4.21 is the 
cumulative amount dissolved vs. time plot for milled Lot 3 crystals and various mixtures 
prepared using the same. The dissolution profile for amorphous CFA-sucrose interactive 
mixture is also shown in Figure 4.21, as it was the mixture that showed the highest 
dissolution rate (Figure 4.14) and is used as a comparison profile. The similarity factor 
(f2) values of the mixtures formulated with Lot 3 crystals (milled) and amorphous CFA-
sucrose interactive mixture are shown in Table 4.7. The dissolution profiles of Lot 3 
crystals (milled)-sucrose interactive mixture was significantly different from the 
interactive mixture containing amorphous CFA. 
Table 4.8 shows the equations following application of the biexponential model 
to amount remaining to dissolve vs time data for the Lot 3 crystals (milled) mixture 
samples and the correlation coefficients of the model fitting. The correlation coefficients 
are greater than 0.991 indicating that the biexponential model fit the dissolution data. 
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Figure 4.21. Representative cumulative percent dissolved versus time profiles for Lot 3 crystals 
(milled), interactive and physical mixtures, thereof, prepared with sucrose (500–1000 µm) carrier 
particles. The dissolution profile of amorphous CFA-sucrose interactive mixture is shown for 
comparison. 
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Table 4.7. Similarity factor (f2) values for mixture samples. 
Comparison f2  statistic value* Inference 
Amorphous CFA-sucrose 
interactive mixture and Lot 3 
crystals (milled) 
70.91 Dissolution profiles are similar 
Amorphous CFA-sucrose 
interactive mixture and Lot 3 
crystals (milled)-sucrose 
physical mixture 
58.45 Dissolution profiles are similar 
Amorphous CFA-sucrose 
interactive mixture and Lot 3 
crystals (milled)-sucrose 
interactive mixture 
19.98 
Dissolution profiles are not 
similar 
*f2 value calculated using Equation 4.9 (Section 4.2.7). f2 values between 50–100 indicate 
similarity between dissolution profiles.116 
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Table 4.8. Biexponential model fit to amount remaining to dissolve vs time data for Lot 3 
crystals (milled) samples. 
Sample Biexponential model equation* 
Correlation 
coefficient (R2) 
 
Lot 3 crystals (milled) 
76.12e-0.016t+16.99e-0.322t 0.992 
78.37e-0.015t+16.66e-0.322t 0.995 
79.22e-0.012t+15.40e-0.319t 0.994 
 
Lot 3 crystals (milled)-sucrose 
physical mixture 
76.23e-0.017t+15.71e-0.336t 0.994 
77.38e-0.016t+13.10e-0.324t 0.992 
75.29e-0.016t+15.99e-0.311t 0.995 
 
Lot 3 crystals (milled)-sucrose 
interactive mixture 
61.12e-0.053t+28.25e-0.311t 0.991 
62.44e-0.052t+30.49e-0.328t 0.998 
60.23e-0.054t+31.55e-0.321t 0.997 
*Biexponential model is of the form Wae-
kat+Wde-
kdt 
 
The initial weights of agglomerated and dispersed particles, Wa and Wd were 
determined which enabled calculation of the weight-fraction of agglomerated particles 
represented by 
da
a
WW
W

 for each mixture sample prepared with milled Lot 3 crystals. 
Results for the weight–fraction of agglomerated particles are shown in Figure 4.22. Two-
way ANOVA with Tukey’s multiple comparison tests was used to evaluate statistical 
significance between the mixtures. The weight-fraction of agglomerated particles was 
significantly lower for the interactive mixture prepared with either coating material, that 
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is, amorphous CFA or Lot 3 crystals (milled) as compared to pure drug and physical 
mixtures. These data indicate that interactive mixing with sucrose carrier was able to 
effectively break down agglomerated particles of amorphous CFA or Lot 3 crystals. 
However the weight-fraction of agglomerated particles in amorphous CFA-sucrose 
interactive mixtures was significantly lower as compared to that in interactive mixtures 
containing Lot 3 crystals. The increased deagglomeration tendency of amorphous 
agglomerates as compared to crystalline agglomerates may be related to the packing 
nature of the amorphous particles which may have formed a more porous agglomerate 
structure as compared to crystalline particles. There was no significant difference in the 
weight-fraction of agglomerated particles in Lot 3 crystals (milled) and physical mixture 
prepared with the same, indicating that low-intensity physical mixing was not able to 
effectively break up drug agglomerates.  
The effective surface area of the agglomerated and dispersed particles, Sa and Sd, 
were calculated from Equation 4.3 and Equation 4.4, respectively. Figure 4.23 shows 
the sum of the Sa and Sd term for the amorphous CFA-sucrose interactive mixture, Lot 3 
crystals (milled), interactive and physical mixtures of Lot 3 crystals (milled). The sum of 
the effective surface area of the agglomerated and dispersed particles from all samples 
containing Lot 3 crystals (milled) were significantly higher than those formulated with 
amorphous CFA. The effective surface area of the drug from interactive mixtures of Lot 
3 crystals was significantly higher compared to that of Lot 3 crystals (milled) and the 
physical mixture. The effective surface area of the drug particles from the interactive 
mixture containing Lot 3 crystals (milled) was 239 (±14) cm2 and was significantly 
higher as compared to 118 (±8.10) cm2 and 113 (±11) cm2 for Lot 3 crystals (milled) and 
138 
 
physical mixture, respectively. The higher effective surface of the drug from interactive 
mixtures containing milled crystalline particles as compared to those containing 
amorphous CFA resulted in their faster dissolution rate (Figure 4.21). 
 
 
 
Figure 4.22. Comparison of weight-fraction of agglomerated particles for amorphous CFA-
sucrose interactive mixture, Lot 3 crystals (milled) and interactive and physical mixtures, thereof, 
prepared with sucrose carrier particles based on modeling of dissolution data (Equation 1.45). * 
# ** represents statistical significant comparisons. Each data point represents the average of n=3 
replicates, where the error bars are the standard deviation (SD). 
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Figure 4.23. Comparison of the effective surface areas of agglomerated particles and dispersed 
particles, for amorphous CFA-sucrose interactive mixture, Lot 3 crystals (milled) and interactive 
and physical mixtures, thereof, prepared with sucrose carrier particles. Values calculated using 
Equation 4.3 and Equation 4.4. * # ** represents statistical significant comparisons. Each data 
point represents the average of n=3 replicates, where the error bars are the standard deviation 
(SD). 
The sum of the effective surface areas of the agglomerated and dispersed 
particles, calculated using Equation 4.3 and Equation 4.4 for the various samples were 
calculated as a fraction of the theoretical maximum surface area available for dissolution. 
The theoretical maximum surface area for each sample was calculated from knowledge of 
the specific surface area (SSA) of Lot 3 crystals (milled) measured by nitrogen vapor 
adsorption (Table 4.1) and the amount of drug used in the dissolution experiment. The 
values of the percent total surface area of the different samples are given in Table 4.9.  
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Table 4.9. Percent total surface area Lot 3 crystals (milled) and mixture samples based on 
dissolution data. Theoretical maximum surface area determined using nitrogen vapor adsorption 
analysis. Values represent average (±SD) of n=3 replicates for each sample. 
Sample % Total surface area 
Lot 3 crystals (milled) 14.2 (±1.06) 
Lot 3 crystals (milled)-sucrose physical 
mixture 
14.0 (±1.15) 
Lot 3 crystals (milled)-sucrose interactive 
mixture 
29.7 (±0.124)* # 
*# represents statistical significant comparisons; *vs Lot 3 crystals (milled) and #vs physical 
mixture. 
 
 Based on Figure 4.23 and Table 4.9, it was concluded that interactive mixing 
resulted in availability of a larger fraction of the total surface area of the drug particles for 
dissolution. The effective surface area of the drug from milled Lot 3 crystal samples was 
higher than that of drug from amorphous CFA-sucrose interactive mixtures. Interactive 
mixing of milled crystalline particles with sucrose carrier further contributed to the 
effective surface area increase and dissolution rate enhancement. 
 The parameter related to particle size of the agglomerated and dispersed particles 
was calculated for Lot 3 crystal (milled) samples and compared to that obtained for 
amorphous CFA-sucrose interactive mixture. Figure 4.24 shows the values for the 
parameter related to agglomerate particle size (raρa) term. The raρa term was significantly 
lower for samples formulated with Lot 3 crystal (milled) as compared to those prepared 
with amorphous CFA due to milling of crystalline material that caused particle size 
reduction. The value for the raρa was 3.06 (±5.55×10-2) mg/cm2 for the interactive 
mixtures prepared with Lot 3 crystals (milled) as compared to 11.5 (±1.84) mg/cm2 and 
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9.99 (±0.288) mg/cm2 for the milled crystals and physical mixture, respectively. Similar 
to the results of amorphous CFA mixtures discussed above and shown in Figure 4.17, 
interactive mixing was able to cause size reduction of the agglomerated particles.  
 
 
Figure 4.24. Comparison of parameter related to agglomerate particle size (
aar  ) for amorphous 
CFA-sucrose interactive mixture, Lot 3 crystals (milled) and interactive and physical mixtures, 
thereof, prepared with sucrose carrier particles. Values calculated using Equation 4.7. 
* # ** represents statistical significant comparisons. Each data point represents the average of 
n=3 replicates, where the error bars are the standard deviation (SD). 
  
The parameter related to particle size of dispersed particles,  rdρd term was  not 
significantly different across the samples prepared using milled Lot 3 crystals (Figure 
4.25)  indicating that interactive mixing did not appear to significantly affect the size of 
the dispersed particles. This indicates that there is no milling or particle size reduction of 
the drug during mixing. In contrast, the rdρd term for the samples made with Lot 3 
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crystals was significantly lower than that for amorphous CFA-sucrose interactive 
mixtures. For example, the rdρd term for Lot 3 crystals (milled)-sucrose interactive 
mixture was 0.505 (±1.35×10-2) mg/cm2 and that of amorphous CFA-sucrose interactive 
mixture was 5.70 (±0.143) mg/cm2. Therefore milling of crystalline particles caused a 
decrease in primary particle size and an increase in effective surface area which was able 
to compensate for the lower solubility of the crystalline form relative to amorphous CFA. 
The radius of milled particles of Lot 3 crystals was calculated from the SSA value 
using vapor adsorption analysis and was found to be 2.36 μm representing the size of the 
dispersed particles. The radius of the agglomerated and dispersed particles in Lot 3 
crystals (milled)-sucrose interactive mixtures was calculated by Equation 4.7 and 
Equation 4.8, respectively. The values were found to be 21.25 (±0.39) μm and 3.50 
(±0.09) μm, respectively. There was good accordance between the size of the dispersed 
particles by vapor adsorption analysis and modeling. 
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Figure 4.25. Comparison of parameter related to dispersed particle size (
ddr  ) for amorphous 
CFA-sucrose interactive mixture, Lot 3 crystals (milled) and interactive and physical mixtures, 
thereof, prepared with sucrose carrier particles. Values calculated using Equation 4.8.* 
represents statistical significant comparisons. Each data point represents the average of n=3 
replicates, where the error bars are the standard deviation (SD). 
 
4.4 Conclusion  
The dissolution rate of CFA was dramatically improved through the use of 
interactive mixtures. The mechanism underlying the improvement in dissolution rate 
upon interactive mixing was investigated by application of a dissolution model relevant 
to heterogeneous particle distributions.  It was demonstrated that the improvement was 
due a lower weight-fraction of agglomerated particles in the interactive mixtures as 
compared to physical mixtures and the pure drug itself. This further increased availability 
of the drug’s surface area to the dissolution medium. Interactive mixtures had larger 
effective surface areas because the drug agglomerates had been broken down to dispersed 
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drug particles and agglomerate size had been reduced. This effect could not be achieved 
with simple physical mixing. Modeling enabled development of a relationship between 
the rate constants describing surface area change of the agglomerated and dispersed 
particles and a parameter related to particle size.  It was concluded that interactive mixing 
did not affect the particle size of dispersed drug particles but decreased the size and 
number of the agglomerated particles making a larger surface area accessible to the 
solvent for dissolution.  
 Interactive mixtures were formulated with milled particles of Lot 3 crystals in 
order to avoid phase transformation during dissolution which was observed with 
amorphous CFA. Interactive mixtures formulated with Lot 3 crystals (75 % wt. isomer B) 
exhibited a higher dissolution rate as compared to that made with amorphous drug. 
Milling of the crystalline particles to increase surface area compensated for the lower 
solubility of the crystalline form relative to amorphous CFA. As a result, interactive 
mixing may allow the crystalline material to be used as an alternative to the metastable 
amorphous solid, which was shown to undergo solvent-mediated conversion during 
dissolution. 
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Chapter 5: Summary 
Solid-state and solubility studies on the diastereomers of cefuroxime axetil (CFA) 
helped to understand their behavior relevant to pharmaceutical processing and 
dissolution. Thermal analysis utilizing differential scanning calorimetry (DSC) enabled 
construction of a temperature-composition diagram of various compositions of the 
diastereomers, namely, isomer A and isomer B of CFA. The diastereomers were found to 
form a eutectic mixture with a composition of 75 % isomer B and melting point of 124.8 
±0.5 °C. As properties of the drug can vary depending upon the solid phase, construction 
of the phase diagram was important in identifying the eutectic composition. This 
information is important for CFA as it is present in commercial preparations in form of a 
diastereomer mixture and eutectic formation is likely to occur during solid processing 
when diastereomer crystals are brought into intimate contact. 
   Phase solubility studies on diastereomer mixtures revealed that the 
diastereomers form a soluble complex. These results were further confirmed by intrinsic 
dissolution rate (IDR) measurements on diastereomer mixtures of various compositions. 
The results of the IDR studies were in good agreement with the Higuchi dissolution 
model for binary mixtures of interacting components. As a result it was concluded that 
the diastereomers interact or complex in solution, which results in a higher solubility than 
would be predicted by the behavior of the individual diastereomer. Furthermore, this 
means the solubility of CFA is depends upon the diastereomer composition in a nontrivial 
way. Given that CFA suffers from dissolution rate limitations, an optimum diastereomer 
ratio (71 % isomer B: 29 % isomer A) has been identified that can maximize the drug’s 
poor solubility. 
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In this project, interactive mixtures of commercially available amorphous CFA 
and milled particles of the diastereomer eutectic mixture (75 % isomer B) were prepared 
with sucrose carrier particles. Interactive mixtures exhibited a marked improvement in 
dissolution rate when compared with both the physical mixtures and the pure drug. The 
mechanism of dissolution rate enhancement following interactive mixing was attributed 
to a decreased fraction of agglomerated drug particles and smaller sized agglomerates 
leading to an increase in the surface area available for dissolution. Milling of crystalline 
drug and subsequent formulation of the milled particles as interactive mixtures was able 
to result in an increase in effective surface area and compensate for the poor solubility of 
the crystalline forms relative to the amorphous drug.  Formulation of crystalline form of 
CFA is a significant advantage as compared to use of amorphous CFA which undergoes a 
solvent-mediated conversion to more stable crystalline forms. It is possible this strategy 
of interactive mixing can be extended to other drugs that exhibit dissolution rate-limited 
bioavailability and for which maximum dissolution is critical. 
 The major factor that limits the widespread us of interactive mixtures is the drug 
dose that can be incorporated into the formulation. Drug loading is dictated by the 
amount of carrier surface available for interaction. The carrier-to-drug ratio in interactive 
mixture formulations ranges from 5:1 to 10 such that for high dose drugs such as CFA, 
large amounts of carrier are necessary to avoid formation of multiple drug layers that can 
impede drug dissolution. This in turn leads to administration of impractical amounts of 
formulation to deliver the required drug dose. Despite this problem, if the dissolution rate 
can be improved upon formulation of interactive mixtures, the necessity to deliver large 
drug doses to produce an equivalent oral bioavailability may be avoided. Another 
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important factor that needs consideration is the effect that added excipients may have on 
the stability of drug-carrier interactive mixtures. In one study, addition of magnesium 
stearate resulted in segregation of aspirin-lactose mixtures. Alteration of electrostatic 
attraction between the drug and carrier caused drug displacement from the carrier 
surface.122  Therefore the effect of excipient such as surfactants, lubricants and 
disintegrants that are commonly added to solid dosage forms requires assessment when 
considering formulation of interactive mixtures in tablet or capsule dosage forms. 
 Despite the problems associated with interactive mixture formulation, it is a 
suitable option for dissolution rate enhancement of CFA.  Thermal degradation of CFA 
can limit the feasibility of developing a solid dispersion formulation and the lack of 
ionizable functional groups on the CFA molecule precludes the possibility of developing 
a salt form. Therefore further development of a binary drug-carrier interactive mixture 
with excipients such as surfactants and disintegrants which can aid in dissolution rate 
enhancement is a viable formulation approach to improve the dissolution rate of CFA. 
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Appendix: DSC Analyses of Diastereomer Mixtures 
A.1. Sample Preparation 
The samples for DSC analyses were prepared and analyzed as described in 
Section 2.2.4 (Chapter 2).  
A.2. Results  
The following figures (Figure A.1–A.11) show the DSC thermograms obtained at 
each heating rate: 1, 2 and 3 °C/min (n=1 replicate is shown at each heating rate) and plot 
of peak melting temperature versus heating rate for diastereomer mixture samples 
ranging in composition from 0 % to 85 % isomer B.  
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Figure A.1. (a) DSC thermogram of Lot 1 crystals (form AI) at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak melting temperature versus 
heating rate. Values represent average of n=2 replicates at each heating rate and error bars are standard deviation.
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Figure A.2. (a) DSC thermogram of diastereomer mixture containing 10 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak 
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm. 
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations. 
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Figure A.3. (a) DSC thermogram of diastereomer mixture containing 20 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak 
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm. 
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations. 
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Figure A.4. (a) DSC thermogram of diastereomer mixture containing 30 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak 
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm 
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations. 
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Figure A.5. (a) DSC thermogram of diastereomer mixture containing 40 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak 
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm 
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations. 
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Figure A.6. (a) DSC thermogram of diastereomer mixture containing 50 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak 
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm 
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations. 
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Figure A.7. (a) DSC thermogram of diastereomer mixture containing 60 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak 
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm. 
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations. 
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Figure A.8. (a) DSC thermogram of diastereomer mixture containing 70 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak 
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm. 
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations. 
  
1
6
5
 
 
 
 
Figure A.9. (a) DSC thermogram of diastereomer mixture containing 75 % isomer B (b) Plot of peak melting temperature versus heating rate for 
eutectic endotherm  Values represent average of n=2 replicates at each heating rate and error bars are standard deviation. 
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Figure A.10. (a) DSC thermogram of diastereomer mixture containing 80 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak 
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm. 
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations. 
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Figure A.11 (a) DSC thermogram of diastereomer mixture containing 85 % isomer B at three heating rates: 1, 2 and 3 °C/min (b) Plot of peak 
melting temperature versus heating rate for eutectic endotherm (c) Plot of peak melting temperature versus heating rate for liquidus endotherm. 
Values represent average of n=2 replicates at each heating rate and error bars are standard deviations. 
